
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended February 29, 2020

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____
Commission file number 0-50761

AngioDynamics, Inc.

(Exact name of registrant as specified in its charter)



angiodynamics

Delaware

(State or other jurisdiction of
incorporation or organization)

11-3146460

(I.R.S. Employer
Identification No.)

14 Plaza Drive, Latham, New York 12110

(Address of principal executive offices and zip code)

(518) 795-1400

Registrant's telephone number, including area code

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol	Name of each exchange on which registered
Common stock, par value \$.01	ANGO	NASDAQ Global Select Market
Preferred Stock Purchase Rights		NASDAQ Global Select Market

Securities registered pursuant to Section 12(g) of the Act:

None

(Title of Class)

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes No

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "large accelerated filer", "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	<input type="checkbox"/>	Accelerated filer	<input checked="" type="checkbox"/>
Non-accelerated filer	<input type="checkbox"/>	Smaller reporting company	<input type="checkbox"/>
Emerging growth company	<input type="checkbox"/>		

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

Indicate the number of shares outstanding of each of the Issuer's classes of common stock, as of the latest practicable date.

<u>Class</u>	<u>Outstanding as of April 6, 2020</u>
Common Stock, par value \$.01	37,694,757

AngioDynamics, Inc. and Subsidiaries**TABLE OF CONTENTS**

	<u>Page</u>
<u>Part I: Financial Information</u>	
Item 1.	<u>Financial Statements</u>
	<u>Consolidated Statements of Operations (unaudited)</u> 3
	<u>Consolidated Statements of Comprehensive Income (Loss) (unaudited)</u> 4
	<u>Consolidated Balance Sheets (unaudited)</u> 5
	<u>Consolidated Statements of Cash Flows (unaudited)</u> 6
	<u>Consolidated Statements of Stockholders' Equity (unaudited)</u> 7
	<u>Notes to Consolidated Financial Statements (unaudited)</u> 9
Item 2.	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u> 29
Item 3.	<u>Quantitative and Qualitative Disclosures About Market Risk</u> 41
Item 4.	<u>Controls and Procedures</u> 42
<u>Part II: Other Information</u>	
Item 1.	<u>Legal Proceedings</u> 43
Item 1A.	<u>Risk Factors</u> 45
Item 2.	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u> 47
Item 3.	<u>Defaults on Senior Securities</u> 47
Item 4.	<u>Mine Safety Disclosures</u> 47
Item 5.	<u>Other Information</u> 47
Item 6.	<u>Exhibits</u> 48

PART 1. FINANCIAL INFORMATION
Item 1. Financial Statements.
AngioDynamics, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands of dollars, except per share data)

	Three Months Ended		Nine Months Ended	
	Feb 29, 2020	Feb 28, 2019	Feb 29, 2020	Feb 28, 2019
Net sales	\$ 69,780	\$ 65,524	\$ 205,825	\$ 199,451
Cost of sales (exclusive of intangible amortization)	29,481	27,361	85,765	84,783
Gross profit	40,299	38,163	120,060	114,668
Operating expenses:				
Research and development	8,395	6,915	22,450	21,365
Sales and marketing	20,934	18,385	60,427	56,054
General and administrative	10,203	8,718	29,651	26,414
Amortization of intangibles	5,019	4,660	13,417	12,599
Change in fair value of contingent consideration	419	609	116	865
Acquisition, restructuring and other items, net	1,565	2,550	4,486	9,700
Total operating expenses	46,535	41,837	130,547	126,997
Operating loss	(6,236)	(3,674)	(10,487)	(12,329)
Other (expenses) income:				
Interest expense, net	(166)	(1,442)	(672)	(3,689)
Other expense, net	(131)	(266)	(67)	(72)
Total other expense, net	(297)	(1,708)	(739)	(3,761)
Loss from continuing operations before income tax benefit	(6,533)	(5,382)	(11,226)	(16,090)
Income tax benefit	(824)	(773)	(1,506)	(2,191)
Net loss from continuing operations	(5,709)	(4,609)	(9,720)	(13,899)
Income from discontinued operations, net of income tax	—	5,405	—	16,366
Net income (loss)	\$ (5,709)	\$ 796	\$ (9,720)	\$ 2,467
Loss per share - continuing operations				
Basic	\$ (0.15)	\$ (0.12)	\$ (0.26)	\$ (0.37)
Diluted	\$ (0.15)	\$ (0.12)	\$ (0.26)	\$ (0.37)
Income per share - discontinued operations				
Basic	\$ 0.00	\$ 0.14	\$ 0.00	\$ 0.44
Diluted	\$ 0.00	\$ 0.14	\$ 0.00	\$ 0.44
Income (loss) per share				
Basic	\$ (0.15)	\$ 0.02	\$ (0.26)	\$ 0.07
Diluted	\$ (0.15)	\$ 0.02	\$ (0.26)	\$ 0.07
Weighted average shares outstanding				
Basic	37,999	37,518	37,924	37,446
Diluted	37,999	37,518	37,924	37,446

The accompanying notes are an integral part of these consolidated financial statements.

AngioDynamics, Inc. and Subsidiaries**CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)**
(unaudited)
(in thousands of dollars)

	Three Months Ended		Nine Months Ended	
	Feb 29, 2020	Feb 28, 2019	Feb 29, 2020	Feb 28, 2019
Net income (loss)	\$ (5,709)	\$ 796	\$ (9,720)	\$ 2,467
Other comprehensive income (loss), before tax:				
Unrealized gain on marketable securities	—	—	—	33
Foreign currency translation	8	173	88	(158)
Other comprehensive income (loss), before tax	8	173	88	(125)
Income tax expense related to items of other comprehensive income	—	—	—	—
Other comprehensive income (loss), net of tax	8	173	88	(125)
Total comprehensive income (loss), net of tax	<u>\$ (5,701)</u>	<u>\$ 969</u>	<u>\$ (9,632)</u>	<u>\$ 2,342</u>

The accompanying notes are an integral part of these consolidated financial statements.

AngioDynamics, Inc. and Subsidiaries

CONSOLIDATED BALANCE SHEETS
(unaudited)
(in thousands of dollars, except share data)

	Feb 29, 2020	May 31, 2019
Assets		
Current assets		
Cash and cash equivalents	\$ 27,160	\$ 227,641
Accounts receivable, net of allowances of \$1,991 and \$1,906 respectively	35,619	43,577
Inventories	54,898	40,071
Prepaid expenses and other	11,369	4,003
Total current assets	129,046	315,292
Property, plant and equipment, net	28,182	24,258
Other assets	13,684	3,835
Intangible assets, net	201,956	145,387
Goodwill	359,093	347,666
Total assets	\$ 731,961	\$ 836,438
Liabilities and stockholders' equity		
Current liabilities		
Accounts payable	\$ 18,304	\$ 22,829
Accrued liabilities	27,445	38,338
Current portion of long-term debt	—	7,500
Current portion of contingent consideration	889	4,635
Other current liabilities	2,074	—
Total current liabilities	48,712	73,302
Long-term debt, net of current portion	14,341	124,407
Contingent consideration, net of current portion	26,405	8,851
Deferred income taxes	24,013	14,542
Other long-term liabilities	8,015	521
Total liabilities	121,486	221,623
Commitments and contingencies (Note 15)		
Stockholders' equity		
Preferred stock, par value \$.01 per share, 5,000,000 shares authorized; no shares issued and outstanding	—	—
Common stock, par value \$.01 per share, 75,000,000 shares authorized; 38,434,757 and 37,984,382 shares issued and 38,064,757 and 37,614,382 shares outstanding at February 29, 2020 and May 31, 2019, respectively	374	372
Additional paid-in capital	560,330	555,040
Retained earnings	56,749	66,469
Treasury stock, 370,000 shares at February 29, 2020 and May 31, 2019, respectively	(5,714)	(5,714)
Accumulated other comprehensive loss	(1,264)	(1,352)
Total Stockholders' Equity	610,475	614,815
Total Liabilities and Stockholders' Equity	\$ 731,961	\$ 836,438

The accompanying notes are an integral part of these consolidated financial statements.

AngioDynamics, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(in thousands of dollars)

	Nine Months Ended	
	Feb 29, 2020	Feb 28, 2019
Cash flows from operating activities:		
Net income (loss)	\$ (9,720)	\$ 2,467
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:		
Depreciation and amortization	17,550	19,158
Non-cash lease expense	1,567	—
Stock based compensation	5,998	7,119
Change in fair value of contingent consideration	116	865
Deferred income taxes	(1,606)	633
Change in accounts receivable allowances	186	(99)
Fixed and intangible asset impairments and disposals	395	689
Write-off of other assets	593	—
Other	70	(5)
Changes in operating assets and liabilities:		
Accounts receivable	7,834	(3,853)
Inventories	(14,036)	(2,702)
Prepaid expenses and other	(9,378)	(1,508)
Accounts payable, accrued and other liabilities	(18,003)	(10,336)
Net cash (used in) provided by operating activities	<u>(18,434)</u>	<u>12,428</u>
Cash flows from investing activities:		
Additions to property, plant and equipment	(5,756)	(2,303)
Acquisition of intangibles	(350)	—
Cash paid for acquisitions	(55,760)	(84,920)
Proceeds from sale of marketable securities	—	1,350
Net cash used in investing activities	<u>(61,866)</u>	<u>(85,873)</u>
Cash flows from financing activities:		
Proceeds from issuance of and borrowings on long-term debt	15,000	55,000
Repayment of long-term debt	(132,500)	(13,750)
Deferred financing costs on long-term debt	(775)	—
Payment of acquisition related contingent consideration	(1,208)	(2,100)
Proceeds (outlays) from exercise of stock options and employee stock purchase plan	(706)	2,023
Net cash provided by (used in) financing activities	<u>(120,189)</u>	<u>41,173</u>
Effect of exchange rate changes on cash and cash equivalents	8	(120)
Decrease in cash and cash equivalents	<u>(200,481)</u>	<u>(32,392)</u>
Cash and cash equivalents at beginning of period	227,641	74,096
Cash and cash equivalents at end of period	<u>\$ 27,160</u>	<u>\$ 41,704</u>
Supplemental disclosure of non-cash investing and financing activities:		
Accrual for capital expenditures incurred during the period	\$ 214	\$ (42)
Fair value of contingent consideration for acquisitions	14,900	25,100
Fair value of acquisition consideration included in other long-term liabilities	—	4,691

The accompanying notes are an integral part of these consolidated financial statements.

AngioDynamics, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(unaudited)
(in thousands of dollars, except share data)

	Common Stock		Additional paid in capital	Retained earnings	Accumulated other comprehensive loss	Treasury Stock		Total
	Shares	Amount				Shares	Amount	
Balance at May 31, 2019	37,984,382	\$ 372	\$ 555,040	\$ 66,469	\$ (1,352)	(370,000)	\$ (5,714)	\$ 614,815
Net loss				(1,275)				(1,275)
Exercise of stock options	48,136	1	530					531
Issuance/Cancellation of restricted stock units	287,087		(2,459)					(2,459)
Purchases of common stock under ESPP	40,270		628					628
Stock-based compensation			1,984					1,984
Other comprehensive loss, net of tax					(151)			(151)
Balance at August 31, 2019	38,359,875	\$ 373	\$ 555,723	\$ 65,194	\$ (1,503)	(370,000)	\$ (5,714)	\$ 614,073
Net loss				(2,736)				(2,736)
Issuance/Cancellation of restricted stock units	4,051							—
Stock-based compensation			2,242					2,242
Other comprehensive income, net of tax					231			231
Balance at November 30, 2019	38,363,926	\$ 373	\$ 557,965	\$ 62,458	\$ (1,272)	(370,000)	\$ (5,714)	\$ 613,810
Net loss				(5,709)				(5,709)
Exercise of stock options	2,500		30					30
Issuance/Cancellation of restricted stock units	8,034		(25)					(25)
Purchases of common stock under ESPP	60,297	1	588					589
Stock-based compensation			1,772					1,772
Other comprehensive income, net of tax					8			8
Balance at February 29, 2020	38,434,757	\$ 374	\$ 560,330	\$ 56,749	\$ (1,264)	(370,000)	\$ (5,714)	\$ 610,475

AngioDynamics, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - continued
(unaudited)
(in thousands of dollars, except share data)

	Common Stock		Additional paid in capital	Retained earnings	Accumulated other comprehensive loss	Treasury Stock		Total
	Shares	Amount				Shares	Amount	
Balance at May 31, 2018	37,594,493	\$ 370	\$ 543,762	\$ 5,129	\$ (952)	(370,000)	\$ (5,714)	\$ 542,595
Net loss				(469)				(469)
Exercise of stock options	71,336	1	607					608
Issuance/Cancellation of restricted stock units	149,446		(460)					(460)
Issuance/Cancellation of performance share units	5,235							—
Purchases of common stock under ESPP	40,547	1	556					557
Stock-based compensation			2,150					2,150
Other comprehensive loss, net of tax					(92)			(92)
Balance at August 31, 2018	37,861,057	\$ 372	\$ 546,615	\$ 4,660	\$ (1,044)	(370,000)	\$ (5,714)	\$ 544,889
Net income				2,140				2,140
Exercise of stock options	10,571		149					149
Issuance/Cancellation of restricted stock units	3,901							—
Stock-based compensation			2,591					2,591
Other comprehensive loss, net of tax					(206)			(206)
Balance at November 30, 2018	37,875,529	\$ 372	\$ 549,355	\$ 6,800	\$ (1,250)	(370,000)	\$ (5,714)	\$ 549,563
Net income				796				796
Exercise of stock options	40,346		603					603
Issuance/Cancellation of restricted stock units	7,703		\$ (49)					(49)
Purchases of common stock under ESPP	32,316		615					615
Stock-based compensation			2,378					2,378
Other comprehensive income, net of tax					173			173
Balance at February 28, 2019	37,955,894	\$ 372	\$ 552,902	\$ 7,596	\$ (1,077)	(370,000)	\$ (5,714)	\$ 554,079

The accompanying notes are an integral part of these consolidated financial statements.

AngioDynamics, Inc. and Subsidiaries**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)****1. CONSOLIDATED FINANCIAL STATEMENTS**

The Consolidated Balance Sheet as of February 29, 2020, the Consolidated Statements of Operations and the Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended February 29, 2020 and February 28, 2019, the Consolidated Statements of Stockholders' Equity for the three months ended February 29, 2020 and February 28, 2019 and the Consolidated Statements of Cash Flows for the nine months ended February 29, 2020 and February 28, 2019 have been prepared by us and are unaudited. The Consolidated Balance Sheet as of May 31, 2019 was derived from audited consolidated financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary to state fairly the financial position, changes in stockholders' equity and comprehensive income, results of operations and cash flows as of and for the period ended February 29, 2020 (and for all periods presented) have been made.

The unaudited interim consolidated financial statements for the three and nine months ended February 29, 2020 and February 28, 2019 include the accounts of AngioDynamics, Inc. and its wholly owned subsidiaries, collectively, the "Company". All intercompany balances and transactions have been eliminated.

On May 31, 2019, the Company completed the sale of the Fluid Management business and all of the assets used primarily in connection with the Fluid Management business (Note 3). As the disposal of this business represents a strategic shift with a major effect on the Company's operations, for all periods presented in our Consolidated Statements of Operations and Comprehensive Loss, all sales, costs, expenses, gains and income taxes attributable to Fluid Management have been reported under the captions, "Income from Discontinued Operations, Net of Income Tax." Cash flows used in or provided by Fluid Management have been reported in the Consolidated Statements of Cash Flows under operating and investing activities.

2. ACQUISITIONS**C3 Wave Tip Location Acquisition**

On December 17, 2019, the Company acquired the C3 Wave tip location asset from Medical Components Inc. for an aggregate purchase price of \$10.0 million with \$5.0 million of potential future contingent consideration related to technical milestones. This acquisition fills a gap in the Vascular Access portfolio and supports the Company's strategic plan. The Company accounted for this acquisition as an asset purchase. The Company recorded the amount paid at closing as inventory of \$0.6 million and intangible assets of a trademark of \$0.9 million and product technology of \$8.5 million. The intangible assets will be amortized over 15 years. The contingent consideration is comprised of technical milestones and will be accounted for when the contingency is resolved or becomes probable and reasonably estimable.

Eximo Acquisition

On October 2, 2019, the Company entered into a share purchase agreement to acquire Eximo Medical, Ltd., a pre-commercial stage medical device company and its proprietary 355nm B Laser Atherectomy technology. The aggregate purchase price of \$60.7 million included an upfront payment of \$45.8 million and contingent consideration with an estimated fair value of \$14.9 million. This acquisition expands and complements the Company's Vascular Interventions and Therapies product portfolio by adding the 355nm B Laser Atherectomy technology which treats Peripheral Artery Disease.

The Company accounted for the Eximo acquisition under the acquisition method of accounting for business combinations. Accordingly, the cost to acquire the assets was allocated to the underlying net assets in proportion to estimates of their respective fair values. The excess of the purchase price over the estimated fair value of the net assets acquired was recorded as goodwill. Goodwill is non-deductible for income tax purposes.

The Company has not disclosed the amount of revenue and earnings for sales of Eximo products since acquisition, nor proforma information, because these amounts are not significant to the Company's financial statements. Acquisition-related costs associated with the Eximo acquisition, which are included in "acquisition, restructuring and other items, net" in the accompanying Consolidated Statements of Operations, were approximately \$0.6 million in fiscal year 2020. The following table summarizes the preliminary aggregate purchase price allocated to the net assets acquired:

(in thousands)	Preliminary allocation	Adjustments ⁽¹⁾	Revised allocation
Accounts receivable	\$ 50	\$ —	\$ 50
Inventory	150	—	150
Prepaid and other current assets	54	—	54
Long-term deposits	51	—	51
Property, plant and equipment	397	—	397
Intangible assets:			
Product technology	59,000	1,300	60,300
Goodwill	12,428	(1,001)	11,427
Total assets acquired	\$ 72,130	\$ 299	\$ 72,429
Liabilities assumed			
Accounts payable	\$ 84	\$ —	\$ 84
Other current liabilities	615	—	615
Deferred tax liabilities	10,771	299	11,070
Total liabilities assumed	\$ 11,470	\$ 299	\$ 11,769
Net assets acquired	\$ 60,660	\$ —	\$ 60,660

(1) Measurement period adjustments are recognized on a prospective basis in the period of change, instead of restating prior periods. There was no impact to reported earnings in connection with these measurement period adjustments for the periods presented. Amounts represent adjustments to the preliminary purchase price allocation first presented in the Company's Quarterly Report on Form 10-Q for the quarter ended November 30, 2019 resulting from revising the Company's purchase price allocation for this acquisition.

The allocation of the purchase price to the assets acquired and liabilities assumed, including the amount allocated to goodwill, is subject to change within the measurement period (up to one year from the acquisition date) as additional information that existed at the date of the acquisition related to the values of assets acquired and liabilities assumed is obtained.

The value assigned to the product technology was derived using the multi-period excess earnings method under the income approach. This approach estimates the excess earnings generated over the lives of the customers that existed as of the acquisition date and discounts such earnings to present value. The product technology is deemed to have a useful life of fifteen years and will be amortized on a straight-line basis over the useful life.

The goodwill arising from the acquisition consists largely of synergies and economies of scale the Company hopes to achieve from combining the acquired assets with the Company's current operations.

RadiaDyne Acquisition

On September 21, 2018, the Company acquired RadiaDyne, a privately held medical diagnostic and device company that designs and develops patient dose monitoring technology to improve cancer treatment outcomes. The aggregate purchase price of \$75.0 million included an upfront payment of \$47.9 million, contingent consideration with an estimated fair value of \$22.3 million, an indemnification holdback of \$4.6 million and a purchase price holdback of \$0.2 million. The fair value of \$22.3 million in contingent consideration comprises \$16.5 million for the revenue milestones and \$5.8 million for the technical milestones. The \$4.6 million indemnification holdback is recorded in accrued liabilities at February 29, 2020 and the \$0.2 million purchase price holdback was initially recorded in accrued liabilities, and was paid during the third quarter of fiscal year 2019.

This acquisition expands the Company's growing Oncology business by adding RadiaDyne's early-stage, proprietary OARtrac® real-time radiation dose monitoring platform and other market-leading oncology solutions, including the IsoLoc®/ImmobiLoc® and Alatus® balloon stabilizing technologies.

The Company accounted for the RadiaDyne acquisition under the acquisition method of accounting for business combinations. Accordingly, the cost to acquire the assets was allocated to the underlying net assets in proportion to estimates of their respective fair values. The excess of the purchase price over the estimated fair value of the net assets acquired was recorded as goodwill. Goodwill is deductible for income tax purposes.

The Company has not disclosed the amount of revenue and earnings for sales of RadiaDyne products since acquisition, nor proforma information, because these amounts are not significant to the Company's financial statements. Acquisition-related costs associated with the RadiaDyne acquisition, which are included in "acquisition, restructuring and other items, net" in the

accompanying Consolidated Statements of Operations, were approximately \$1.6 million in fiscal year 2019. The following table summarizes the preliminary and final aggregate purchase price allocated to the net assets acquired:

(in thousands)	Final allocation
Accounts receivable	\$ 900
Inventory	732
Prepaid and other current assets	98
Property, plant and equipment	133
Intangible assets:	
RadiaDyne trademark	400
OARtrac trademark	200
RadiaDyne legacy product technology	1,500
OARtrac product technology	18,900
RadiaDyne customer relationships	4,600
Goodwill	47,982
Total assets acquired	\$ 75,445
Liabilities assumed	
Accounts payable	\$ 352
Accrued expenses	106
Total liabilities assumed	\$ 458
Net assets acquired	\$ 74,987

The Company finalized the allocation of the purchase price to the assets acquired and liabilities assumed in the fourth quarter of FY19.

The values assigned to the RadiaDyne and OARtrac trademark and product technologies were derived using the relief-from-royalties method under the income approach. This approach is used to estimate the cost savings that accrue for the owner of an intangible asset who would otherwise have to pay royalties or licensing fees on revenues earned through the use of the asset if they had not owned the rights to use the assets. The net after-tax royalty savings are calculated for each year in the remaining economic life of the intangible asset and discounted to present value. The trademarks are deemed to have a useful life of five to seven years and the product technologies are deemed to have a useful life of seven to ten years. Both are amortized on a straight-line basis over their useful life.

The value assigned to customer relationships was derived using the multi-period excess earnings method under the income approach. This approach estimates the excess earnings generated over the lives of the customers that existed as of the acquisition date and discounts such earnings to present value. Customer relationships are amortized on a straight-line basis over fifteen years.

The goodwill arising from the acquisition consists largely of synergies and economies of scale the Company hopes to achieve from combining the acquired assets with the Company's current operations.

BioSentry Acquisition

On August 14, 2018, the Company acquired the BioSentry product from Surgical Specialties, LLC ("SSC"), for an aggregate purchase price of \$39.8 million of which \$37.0 million was paid on August 14, 2018 and \$2.8 million was recorded as contingent consideration. The contingent consideration liability was recorded at fair value and was paid in the fourth quarter of fiscal year 2019 upon fulfillment of hydrogel orders by SSC.

The Company accounted for the BioSentry acquisition under the acquisition method of accounting for business combinations. Accordingly, the cost to acquire the assets was allocated to the underlying net assets in proportion to estimates of their respective fair values. The excess of the purchase price over the estimated fair value of the net assets acquired was recorded as goodwill. Goodwill is deductible for income tax purposes.

The Company has not disclosed the amount of revenue and earnings for sales of BioSentry products since acquisition, nor proforma information, because these amounts are not significant to the Company's financial statements. Acquisition-related costs associated with the BioSentry acquisition, which are included in "acquisition, restructuring and other items, net" in the

accompanying Consolidated Statements of Operations, were approximately \$1.0 million in fiscal year 2019. The following table summarizes the preliminary and revised final purchase price allocated to the net assets acquired:

(in thousands)	Final allocation
Inventory	\$ 50
Property, plant and equipment	10
Intangible assets:	
BioSentry trademark	2,500
BioSentry product technology	20,900
Customer relationships	2,600
Goodwill	13,740
Net assets acquired	<u>\$ 39,800</u>

The Company finalized the allocation of the purchase price to the assets acquired and liabilities assumed in the fourth quarter of FY19.

The values assigned to the BioSentry trademark and product technologies were derived using the relief-from-royalties method under the income approach. This approach is used to estimate the cost savings that accrue for the owner of an intangible asset who would otherwise have to pay royalties or licensing fees on revenues earned through the use of the asset if they had not owned the rights to use the assets. The net after-tax royalty savings are calculated for each year in the remaining economic life of the intangible asset and discounted to present value. The trademark and product technologies are deemed to have a fifteen year useful life and are amortized on a straight-line basis over their useful life.

The value assigned to customer relationships was derived using the multi-period excess earnings method under the income approach. This approach estimates the excess earnings generated over the lives of the customers that existed as of the acquisition date and discounts such earnings to present value. Customer relationships are amortized on a straight-line basis over ten years.

The goodwill arising from the acquisition consists largely of synergies and economies of scale the Company hopes to achieve from combining the acquired assets with the Company's current operations.

3. DIVESTITURES

Fluid Management

On May 31, 2019, the Company completed the sale of the NAMIC Fluid Management business (the "Divestiture") and all of the assets used primarily in connection with the Fluid Management business to Medline Industries, Inc. ("Medline") pursuant to an asset purchase agreement dated April 17, 2019 (the "Asset Purchase Agreement"). Total consideration received by the Company for the Divestiture in the fourth quarter of fiscal year 2019 was \$169.2 million in cash and resulted in a gain of \$46.6 million after working capital adjustments of \$0.6 million. The gain was recorded in discontinued operations. On June 3, 2019, a portion of the net proceeds were used to retire the outstanding balance on the Term Loan and Revolving Facility and the remaining net proceeds will continue to be invested in the business.

Pursuant to a transition services agreement entered into and effective on the closing of the transaction, the Company will supply certain services to Medline. Medline will receive certain legal, human resource, tax, accounting and information technology services from the Company for a period generally not to exceed 24 months.

As a result of the Divestiture, the results of operations from the Fluid Management business are reported in the accompanying Consolidated Statements of Operations as "Income from discontinued operations, net of income tax" for the three and nine months ended February 28, 2019. The following table summarizes the financial results of our discontinued operations:

(in thousands)	Three Months Ended Feb 28, 2019	Nine Months Ended Feb 28, 2019
Net sales	\$ 20,818	\$ 63,733
Cost of sales (exclusive of amortization)	12,290	38,134
Gross profit	8,528	25,599
Operating expenses		
Research and development	295	870
Sales and marketing	1,028	3,061
General and administrative	62	198
Amortization of intangibles	682	2,047
Total operating expenses	2,067	6,176
Operating income	6,461	19,423
Income from discontinued operations before income taxes	6,461	19,423
Income tax expense	1,056	3,057
Income from discontinued operations	\$ 5,405	\$ 16,366

In accordance with accounting principles generally accepted in the United States ("GAAP"), only expenses specifically identifiable and related to a business to be disposed may be allocated to discontinued operations. As such, the selling and marketing, research and development and general and administrative expenses recorded in discontinued operations include corporate costs incurred directly in support of the Fluid Management portfolio.

Total operating and investing cash flows of discontinued operations for the nine months ended February 28, 2019 is comprised of the following, which excludes the effect of income taxes:

(in thousands)	Nine Months Ended Feb 28, 2019
Net cash provided by operating activities	841
Net cash provided by investing activities	759

4. REVENUE FROM CONTRACTS WITH CUSTOMERS

Revenue Recognition

Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.

The Company has one primary revenue stream which is the sales of its products.

Disaggregation of Revenue

The following tables summarize net product revenue by Global Business Unit ("GBU") and geography for the three and nine months ended February 29, 2020 and February 28, 2019:

(in thousands)	Three months ended Feb 29, 2020			Three months Ended Feb 28, 2019		
	United States	International	Total	United States	International	Total
Net sales						
Vascular Interventions & Therapies	\$ 26,788	\$ 3,764	\$ 30,552	\$ 26,294	\$ 3,004	\$ 29,298
Vascular Access	20,018	4,624	24,642	18,952	3,396	\$ 22,348
Oncology	8,083	6,503	14,586	8,154	5,724	\$ 13,878
Total	\$ 54,889	\$ 14,891	\$ 69,780	\$ 53,400	\$ 12,124	\$ 65,524

(in thousands)	Nine months ended Feb 29, 2020			Nine months Ended Feb 28, 2019		
	United States	International	Total	United States	International	Total
Net sales						
Vascular Interventions & Therapies	\$ 80,065	\$ 10,551	\$ 90,616	\$ 79,386	\$ 9,484	\$ 88,870
Vascular Access	57,865	12,720	70,585	59,480	10,381	69,861
Oncology	25,451	19,173	44,624	22,329	18,391	40,720
Total	<u>\$ 163,381</u>	<u>\$ 42,444</u>	<u>\$ 205,825</u>	<u>\$ 161,195</u>	<u>\$ 38,256</u>	<u>\$ 199,451</u>

Net Product Revenue

The Company's products consist of a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company's devices are generally used in minimally invasive, image-guided procedures. Most of the Company's products are intended to be used once and then discarded, or they may be implanted for short or long term use. The Company sells its products to its distribution partners and to end users, such as interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists and critical care nurses.

Contracts and Performance Obligations

The Company contracts with its customers based on customer purchase orders, which in many cases are governed by master purchasing agreements. The Company's contracts with customers are generally for product only, and do not include other performance obligations such as services or other material rights. As part of its assessment of each contract, the Company evaluates certain factors including the customer's ability to pay (or credit risk). For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations.

Transaction Price and Allocation to Performance Obligations

Transaction prices of products are typically based on contracted rates. Product revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products to a customer. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method. As such, revenue is recorded net of rebates, returns and other deductions.

If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products underlying each performance obligation. The Company has standard pricing for its products and determines standalone selling prices based on the price at which the performance obligation is sold separately.

Revenue Recognition

Revenue is recognized when control of the product is transferred to the customer (i.e., when the Company's performance obligation is satisfied), which occurs at a point in time, and may be upon shipment from the Company's manufacturing site or delivery to the customer's named location, based on the contractual shipping terms of a contract.

In determining whether control has transferred, the Company considers if there is a present right to payment from the customer and when physical possession, legal title and risks and rewards of ownership have transferred to the customer.

The Company typically invoices customers upon satisfaction of identified performance obligations. As the Company's standard payment terms are 30 to 90 days from invoicing, the Company does not provide any significant financing to its customers.

Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.

Variable Consideration

Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established for discounts, returns, rebates and allowances that are offered within contracts

between the Company and its customers. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as a current liability.

Rebates and Allowances: The Company provides certain customers with rebates and allowances that are explicitly stated in the Company's contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. The Company establishes a liability for such amounts, which is included in accrued expenses in the accompanying Consolidated Balance Sheets. These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes and administrative fees the Company is required to pay to group purchasing organizations.

Product Returns: The Company generally offers customers a limited right of return. Product returns after 30 days must be pre-approved by the Company and customers may be subject to a 20% restocking charge. To be accepted, a returned product must be unadulterated, undamaged and have at least twelve months remaining prior to its expiration date. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities using its historical product return information and considers other factors that it believes could significantly impact its expected returns, including product recalls. During the nine months ended February 29, 2020, such product returns were not material.

Contract Balances with Customers

A receivable is recognized in the period the Company ships the product. Payment terms on invoiced amounts are based on contractual terms with each customer and generally coincide with revenue recognition. Accordingly, the Company does not have any contract assets associated with the future right to invoice its customers. In some cases, if control of the product has not yet transferred to the customer or the timing of the payments made by the customer precedes the Company's fulfillment of the performance obligation, the Company recognizes a contract liability that is included in deferred revenue in the accompanying Consolidated Balance Sheets.

The following table presents changes in the Company's receivables, contract assets and contract liabilities with customers:

(in thousands)	Feb 29, 2020	May 31, 2019
Receivables	\$ 35,619	\$ 43,577
Contract assets	\$ —	\$ —
Contract liabilities	\$ 612	\$ 681

During the nine months ended February 29, 2020, the Company recognized \$1.6 million in revenue that was included in contract liabilities as of the beginning of the period. This was offset by additions to contract liabilities of \$1.6 million in the first nine months of the year.

Costs to Obtain or Fulfill a Customer Contract

Under ASC 606, the Company recognizes an asset for incremental costs of obtaining a contract with a customer if it expects to recover those costs. The Company's sales incentive compensation plans qualify for capitalization since these plans are directly related to sales achieved during a period of time. However, the Company has elected the practical expedient under ASC 340-40-25-4 to expense the costs as they are incurred within selling and marketing expenses since the amortization period is less than one year.

The Company accounts for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products. Shipping and handling costs, associated with the distribution of finished products to customers, are recorded in costs of goods sold and are recognized when the related finished product is shipped to the customer. Amounts charged to customers for shipping are recorded in net sales.

5. INVENTORIES

Inventories are stated at lower of cost and net realizable value (using the first-in, first-out method). Inventories consisted of the following:

(in thousands)	Feb 29, 2020	May 31, 2019
Raw materials	\$ 21,304	\$ 16,045
Work in process	9,385	6,786
Finished goods	24,209	17,240
Inventories	<u>\$ 54,898</u>	<u>\$ 40,071</u>

The Company periodically reviews for both obsolescence and loss of value. The Company makes assumptions about the future demand for and market value of the inventory. Based on these assumptions, the Company estimates the amount of obsolete, expiring and slow moving inventory. The total inventory reserve at February 29, 2020 and May 31, 2019 was \$4.0 million and \$4.2 million, respectively. Of the \$4.0 million reserve as of February 29, 2020 and the \$4.2 million reserve as of May 31, 2019, \$0.3 million and \$0.4 million, respectively, relates to the inventory reserve for Acculis inventory as a result of the recall announced in the fourth quarter of fiscal year 2017. In addition, as of February 29, 2020 and May 31, 2019, \$0.7 million relates to a specific reserve related to the termination of an agreement with a Japanese distributor in the second quarter of fiscal year 2018.

6. GOODWILL AND INTANGIBLE ASSETS

Intangible assets other than goodwill are amortized over their estimated useful lives on either a straight-line basis or proportionately to the benefit being realized. Useful lives range from two to eighteen years. The Company periodically reviews the estimated useful lives of its intangible assets and reviews such assets or asset groups for impairment whenever events or changes in circumstances indicate that the carrying value of the assets or asset groups may not be recoverable. If an intangible asset or asset group is considered to be impaired, the amount of the impairment will equal the excess of the carrying value over the fair value of the asset.

Goodwill is not amortized, but rather, is tested for impairment annually or more frequently if impairment indicators arise. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination.

The Company's annual testing for impairment of goodwill was completed as of December 31, 2019. The Company operates as a single operating segment with one reporting unit and consequently evaluates goodwill for impairment based on an evaluation of the fair value of the Company as a whole. The Company determines the fair value of the reporting unit based on the market valuation approach and concluded that it was not more-likely-than-not that the fair value of the Company's reporting unit was less than its carrying value as of December 31, 2019.

Even though the Company determined that there was no goodwill impairment as of December 31, 2019, the future occurrence of a potential indicator of impairment, such as a significant adverse change in legal, regulatory, business or economic conditions or a more-likely-than-not expectation that the reporting unit or a significant portion of the reporting unit will be sold or disposed of, would require an interim assessment for the reporting unit prior to the next required annual assessment as of December 31, 2020. As a result of the current economic environment and the impact that the COVID-19 global pandemic has had on the global capital markets, the Company's market capitalization is below its reporting unit's carrying value as of February 29, 2020. The Company has concluded that this decline in market capitalization is temporary; however, the ultimate scope and scale that the COVID-19 global pandemic has on the Company may necessitate the Company testing goodwill for impairment in the fourth quarter.

The changes in the carrying amount of goodwill for the nine months ended February 29, 2020 were as follows:

(in thousands)	
Goodwill balance at May 31, 2019	\$ 347,666
Addition for Eximo acquisition (Note 2)	11,427
Goodwill balance at February 29, 2020	<u>\$ 359,093</u>

Intangible assets consisted of the following:

(in thousands)	Feb 29, 2020		
	Gross carrying value	Accumulated amortization	Net carrying value
Product technologies	\$ 251,773	\$ (85,105)	\$ 166,668
Customer relationships	60,149	(29,005)	31,144
Trademarks	10,150	(6,640)	3,510
Licenses	6,087	(5,453)	634
	<u>\$ 328,159</u>	<u>\$ (126,203)</u>	<u>\$ 201,956</u>

(in thousands)	May 31, 2019		
	Gross carrying value	Accumulated amortization	Net carrying value
Product technologies	\$ 182,971	\$ (75,412)	\$ 107,559
Customer relationships	60,166	(25,950)	34,216
Trademarks	9,300	(6,404)	2,896
Licenses	5,752	(5,036)	716
	<u>\$ 258,189</u>	<u>\$ (112,802)</u>	<u>\$ 145,387</u>

Amortization expense for the three months ended February 29, 2020 and February 28, 2019 was \$5.0 million and \$4.7 million, respectively. Amortization expense for the nine months ended February 29, 2020 and February 28, 2019 was \$13.4 million and \$12.6 million, respectively.

Expected future amortization expense related to the intangible assets is as follows:

(in thousands)	
Remainder of 2020	\$ 4,856
2021	18,607
2022	18,003
2023	17,941
2024	16,367
2025 and thereafter	126,182
	<u>\$ 201,956</u>

7. ACCRUED LIABILITIES

Accrued liabilities consisted of the following:

(in thousands)	Feb 29, 2020	May 31, 2019
Payroll and related expenses	\$ 11,159	\$ 14,987
Royalties	2,015	2,088
Accrued severance	1,020	504
Sales and franchise taxes	631	807
Outside services	2,347	3,514
Litigation matters	—	2,700
Indemnification holdback	4,986	4,807
Other	5,287	8,931
	<u>\$ 27,445</u>	<u>\$ 38,338</u>

8. LONG TERM DEBT

On June 3, 2019 and in connection with the completion of the Fluid Management divestiture, the Company repaid all amounts outstanding under its existing Credit Agreement and entered into a new Credit Agreement with the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, and Bank of America, N.A. and KeyBank National Association, as co-syndication agents.

The Credit Agreement provides for a \$125.0 million secured revolving credit facility (the “Revolving Facility”), which includes an uncommitted expansion feature that allows the Company to increase the total revolving commitments and/or add new tranches of term loans in an aggregate amount not to exceed \$75.0 million. The proceeds may be used to refinance certain existing indebtedness of the Company and its subsidiaries, to finance the working capital needs, and for general corporate purposes (including permitted acquisitions), of the Company and its subsidiaries.

The Credit Agreement has a five year maturity. Interest on the facility will be based, at the Company’s option, on a base rate of LIBOR plus an applicable margin tied to the Company’s total leverage ratio and having ranges between 0.25% and 0.75% for base rate loans and between 1.25% and 1.75% for LIBOR loans. After default, the interest rate may be increased by 2.0%. The facility will also carry a commitment fee of 0.20% to 0.25% per annum on the unused portion.

The Company's obligations under the Revolving Facility are unconditionally guaranteed, jointly and severally, by the Company's material direct and indirect domestic subsidiaries (the “Guarantors”). All obligations of the Company and the Guarantors under the Revolving Facility are secured by first priority security interests in substantially all of the assets of the Company and the Guarantors.

The Credit Agreement includes customary representations, warranties and covenants, and acceleration, indemnity and events of default provisions, including, among other things, two quarterly financial covenants as follows:

- maximum leverage ratio of consolidated total indebtedness* to consolidated EBITDA* of not greater than 3.00 to 1.00 (during certain periods following material acquisitions the ratio shall be increased to 3.50 to 1.00).
- fixed charge coverage ratio of consolidated EBITDA minus consolidated capital expenditures to consolidated interest expense paid or payable in cash plus scheduled principal payments in respect of indebtedness under the Credit Agreement of not less than 1.25 to 1.00.

* The definitions of consolidated total indebtedness and consolidated EBITDA are maintained in the credit agreement included as an exhibit to Form 8-k filed on June 6, 2019.

As of February 29, 2020, there was \$15.0 million outstanding balance on the Revolving Facility. As of February 29, 2020 and May 31, 2019, the carrying value of long-term debt approximated its fair market value.

The interest rate on the Revolving Facility at February 29, 2020 was 2.92%.

The Company was in compliance with the Credit Agreement covenants as of February 29, 2020.

The Company's maturities of principal obligations under the Credit Agreement are as follows as of February 29, 2020:

(in thousands)	
Revolving Facility ⁽¹⁾	\$ 15,000
Less: Unamortized debt issuance costs	(659)
Total	\$ 14,341

(1) The Revolving Facility is due in fiscal year 2024.

9. INCOME TAXES

The Company provides for income taxes at the end of each interim period based on the estimated effective tax rate for the full fiscal year adjusted for any discrete events, which are recorded in the period that they occur. The estimated annual effective tax rate prior to discrete items was 12.9% as of the third quarter of fiscal 2020, as compared to 14.0% for the same period in fiscal 2019. In fiscal 2020, the Company's effective tax rate differs from the U.S. statutory rate primarily due to the impact of the valuation allowance, foreign taxes, and other non-deductible permanent items (such as non-deductible meals and entertainment, Section 162(m) excess compensation and non-deductible share based compensation).

The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realization of deferred tax assets requires significant management judgment. In determining whether its deferred tax assets are more likely than not realizable, the Company evaluated all available positive and negative evidence, and weighted the evidence based on its objectivity. Evidence that the Company considered included its history of net operating losses, which resulted in the Company recording a full valuation allowance for its deferred tax assets in fiscal 2016, except the naked credit deferred tax liability.

Based on the review of all available evidence, the Company determined that it has not yet attained a sustained level of profitability and the objectively verifiable negative evidence outweighed the positive evidence. Therefore, the Company has provided a valuation allowance on its federal and state net operating loss carryforwards, federal and state R&D credit carryforwards and other net deferred tax assets that have a limited life and are not supportable by the naked credit deferred tax liability sourced income as of February 29, 2020. The Company will continue to assess the level of the valuation allowance required. If sufficient positive evidence exists in future periods to support a release of some or all of the valuation allowance, such a release would likely have a material impact on the Company's results of operations.

10. SHARE-BASED COMPENSATION

The Company has two stock-based compensation plans that provide for the issuance of up to approximately 11.3 million shares of common stock. The 2004 Stock and Incentive Award Plan (the "2004 Plan") provides for the grant of incentive options to the Company's employees and for the grant of non-statutory stock options, restricted stock, stock appreciation rights, performance units, performance shares and other incentive awards to the Company's employees, directors and other service providers. The Company also has an employee stock purchase plan.

For the three months ended February 29, 2020 and February 28, 2019, share-based compensation expense was \$1.8 million and \$2.4 million, respectively. For the nine months ended February 29, 2020 and February 28, 2019, share-based compensation expense was \$6.0 million and \$7.1 million, respectively.

During the nine months ended February 29, 2020 and February 28, 2019, the Company granted stock options and restricted stock units under the 2004 Plan to certain employees and members of the Board of Directors. Stock option awards are valued using the Black-Scholes option-pricing model and then amortized on a straight-line basis over the requisite service period of the award. Restricted stock unit awards are valued based on the closing trading value of the Company's shares on the date of grant and then amortized on a straight-line basis over the requisite service period of the award.

During the nine months ended February 29, 2020 and February 28, 2019, the Company granted performance share units under the 2004 Plan to certain employees. The awards may be earned by achieving relative performance levels over the year requisite service period. The performance criteria are based on achieving certain performance targets and the total shareholder return ("TSR") of the Company's common stock relative to the TSR of the common stock of a pre-defined industry peer-group. The fair value of these awards are based on the closing trading value of the Company's shares on the date of grant and use a Monte Carlo simulation model.

As of February 29, 2020, there was \$14.0 million of unrecognized compensation expense related to share-based payment arrangements. These costs are expected to be recognized over a weighted-average period of approximately four years. The Company has sufficient shares to satisfy expected share-based payment arrangements.

11. EARNINGS PER SHARE

Basic earnings per share is based on the weighted average number of common shares outstanding without consideration of potential common stock. Diluted earnings per share includes the dilutive effect of potential common stock consisting of stock options, restricted stock units and performance stock units, provided that the inclusion of such securities is not anti-dilutive. In periods with a net loss, stock options and restricted stock units are not included in the computation of diluted loss per share as the impact would be anti-dilutive.

The following table reconciles basic to diluted weighted-average shares outstanding for the three and nine months ended February 29, 2020 and February 28, 2019 (in thousands):

(in thousands)	Three Months Ended		Nine Months Ended	
	Feb 29, 2020	Feb 28, 2019	Feb 29, 2020	Feb 28, 2019
Basic	37,999	37,518	37,924	37,446
Effect of dilutive securities	—	—	—	—
Diluted	37,999	37,518	37,924	37,446
Securities excluded as their inclusion would be anti-dilutive	2,699	2,293	2,656	2,293

12. SEGMENT AND GEOGRAPHIC INFORMATION

The Company considers the business to be a single operating segment engaged in the development, manufacture and sale of medical devices for vascular access, peripheral vascular disease and oncology on a global basis. The Company's chief operating decision maker, the President and Chief Executive Officer (CEO), evaluates the various global product portfolios on a net sales basis. Executives reporting to the CEO include those responsible for commercial operations, manufacturing operations, regulatory and quality and certain corporate functions. The CEO evaluates profitability, investment and cash flow metrics on a consolidated worldwide basis due to shared infrastructure and resources.

The table below summarizes net sales by Global Business Unit:

(in thousands)	Three Months Ended		Nine months ended	
	Feb 29, 2020	Feb 28, 2019	Feb 29, 2020	Feb 28, 2019
Net sales				
Vascular Interventions & Therapies	\$ 30,552	\$ 29,298	\$ 90,616	\$ 88,870
Vascular Access	24,642	22,348	70,585	69,861
Oncology	14,586	13,878	44,624	40,720
Total	\$ 69,780	\$ 65,524	\$ 205,825	\$ 199,451

The table below presents net sales by geographic area based on external customer location:

(in thousands)	Three Months Ended		Nine months ended	
	Feb 29, 2020	Feb 28, 2019	Feb 29, 2020	Feb 28, 2019
Net sales				
United States	\$ 54,889	\$ 53,400	\$ 163,381	\$ 161,195
International	14,891	12,124	42,444	38,256
Total	\$ 69,780	\$ 65,524	\$ 205,825	\$ 199,451

13. FAIR VALUE

On a recurring basis, the Company measures certain financial assets and financial liabilities at fair value based upon quoted market prices, where available. Where quoted market prices or other observable inputs are not available, the Company applies valuation techniques to estimate fair value. FASB ASC Topic 820, *Fair Value Measurements and Disclosures*,

establishes a three-level valuation hierarchy for disclosure of fair value measurements. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:

- Level 1 - Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.
- Level 2 - Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.
- Level 3 - Inputs to the valuation methodology are unobservable inputs based on management's best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.

The Company's financial instruments include cash and cash equivalents, accounts receivable, accounts payable and contingent consideration. The carrying amount of cash and cash equivalents, accounts receivable, and accounts payable approximates fair value due to the immediate or short-term maturities. The Company's recurring fair value measurements using significant unobservable inputs (Level 3) relate to contingent consideration liabilities.

The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis as of February 29, 2020 and May 31, 2019:

(in thousands)	Fair Value Measurements using inputs considered as:			Fair Value at Feb 29, 2020
	Level 1	Level 2	Level 3	
Financial Liabilities				
Contingent consideration for acquisition earn outs	\$ —	\$ —	\$ 27,294	\$ 27,294
Total Financial Liabilities	\$ —	\$ —	\$ 27,294	\$ 27,294

(in thousands)	Fair Value Measurements using inputs considered as:			Fair Value at May 31, 2019
	Level 1	Level 2	Level 3	
Financial Liabilities				
Contingent consideration for acquisition earn outs	\$ —	\$ —	\$ 13,486	\$ 13,486
Total Financial Liabilities	\$ —	\$ —	\$ 13,486	\$ 13,486

There were no transfers between Level 1, 2 and 3 for the three and nine months ended February 29, 2020.

The table below presents the changes in fair value components of Level 3 instruments in the three and nine months ended February 29, 2020:

(in thousands)	Three Months Ended Feb 29, 2020
	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Balance, November 30, 2019	\$ 26,875
Total gains or losses (realized/unrealized):	
Change in present value of contingent consideration ⁽¹⁾	419
Balance, February 29, 2020	<u>\$ 27,294</u>

(in thousands)	Nine Months Ended Feb 29, 2020
	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Balance, May 31, 2019	\$ 13,486
Total gains or losses (realized/unrealized):	
Contingent consideration liability recorded as the result of the acquisitions (Note 2)	14,900
Change in present value of contingent consideration ⁽¹⁾	116
Contingent consideration payments	(1,208)
Balance, February 29, 2020	<u>\$ 27,294</u>

(1) Change in the fair value of contingent consideration is included in earnings and comprised of changes in estimated earn out payments based on projections of Company performance and amortization of the present value discount.

Contingent Consideration for Acquisition Earn Outs

Some of the Company's business combinations involve the potential for the payment of future contingent consideration upon the achievement of certain product development milestones or various other performance conditions. Payment of the additional consideration is generally contingent on the acquired company reaching certain performance milestones, including attaining specified revenue levels or product development targets. Contingent consideration is recorded at the estimated fair value of the contingent payments on the acquisition date. The fair value of the contingent consideration is remeasured at the estimated fair value at each reporting period with the change in fair value recognized as income or expense within change in fair value of contingent consideration in the Consolidated Statements of Operations.

The Company measures the initial liability and remeasures the liability on a recurring basis using Level 3 inputs as defined under authoritative guidance for fair value measurements. The fair value is determined using a discounted cash flow model applied to projected net sales, using probabilities of achieving projected net sales and projected payment dates. Projected net sales are based on the Company's internal projections and extensive analysis of the target market and the sales potential. Increases or decreases in any valuation inputs in isolation may result in a significantly lower or higher fair value measurement in the future.

The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of February 29, 2020:

(in thousands)	Fair Value	Valuation Technique	Unobservable Input	Range
Revenue based payments	\$ 23,926	Discounted cash flow	Discount rate	4% - 5%
			Probability of payment	66% - 100%
			Projected fiscal year of payment	2023 - 2029
Technical milestones	\$ 3,368	Estimated probability	Estimated probability	90%
			Projected year of payment	2020 - 2022
Total	\$ 27,294			

At February 29, 2020, the range of estimated potential undiscounted future contingent consideration that the Company expects to pay as a result of all completed acquisitions is \$34.0 million to \$54.0 million. The milestones, including revenue projections and technical milestones, associated with the contingent consideration must be reached in future periods ranging from fiscal years 2020 to 2029 in order for the associated consideration to be paid.

14. LEASES

Adoption of ASU No. 2016-02, *Leases* (Topic 842)

On June 1, 2019, the Company adopted ASU No. 2016-02 using the modified retrospective approach. This ASU increases transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. Comparative periods prior to adoption have not been retrospectively adjusted.

The Company elected the three practical expedients that permit an entity to a) not reassess whether expired or existing contracts contain leases, b) not reassess lease classification for existing or expired leases, and c) not consider whether previously capitalized initial direct costs would be appropriate under the new standard. Further, the Company has elected to not recognize leases with terms of 12 months or less on the balance sheet, and elected to account for lease and non-lease components as a single component for certain classes of assets.

The adoption of this standard resulted in the recording of an additional lease asset and lease liability of approximately \$5.6 million. The standard did not have a material impact on the Company's Consolidated Statement of Operations, Stockholders Equity or Cash Flows.

Leases

The Company determines if an arrangement is a lease at inception of the contract. The Company has operating leases for buildings, primarily for office space, R&D, manufacturing and warehousing.

Operating lease right-of-use ("ROU") assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Many of the lease agreements contain renewal or termination clauses that are factored into the determination of the lease term if it is reasonably certain that these options would be exercised. The Company recognizes lease expense for these leases on a straight-line basis over the lease term.

The following table presents supplemental balance sheet information related to leases:

(in thousands)	Balance Sheet Location	Feb 29, 2020
Assets		
Operating lease ROU asset	Other assets	\$ 9,628
Liabilities		
Current operating lease liabilities	Other current liabilities	1,879
Non-current operating lease liabilities	Other long-term liabilities	7,724
Total lease liabilities		<u>\$ 9,603</u>

The interest rate implicit in lease agreements is typically not readily determinable, and as such the Company used the incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The incremental borrowing rate is defined as the interest the Company would pay to borrow on a collateralized basis, considering factors such as length of lease term. The following table presents the weighted average remaining lease term and discount rate:

	Feb 29, 2020
Weighted average remaining term (in years)	5.31
Weighted average discount rate	4.2 %

The following table presents the maturities of the lease liabilities:

(in thousands)	Feb 29, 2020
Remainder of 2020	\$ 563
2021	2,190
2022	2,073
2023	2,110
2024	1,562
2025 and thereafter	2,190
Total lease payments	<u>\$ 10,688</u>
Less: Imputed Interest	1,085
Total lease obligations	<u>\$ 9,603</u>
Less: Current portion of lease obligations	1,879
Long-term lease obligations	<u>\$ 7,724</u>

Included in the total lease obligations is a 7-year building operating lease with undiscounted payment obligations of \$6.4 million that commenced during the third quarter of fiscal year 2020. In addition to the total lease obligations presented in the table above, the Company has a 5-year building operating lease with undiscounted payment obligations of \$1.5 million that is expected to commence during fiscal year 2020.

During the three and nine months ended February 29, 2020, the Company recognized \$0.9 million and \$2.5 million of operating lease expense, respectively, which includes immaterial short-term leases. As of February 29, 2020, the expenses on the Consolidated Statement of Operations were classified as follows:

(in thousands)	Three Months Ended	Nine Months Ended
Cost of sales	\$ 297	\$ 856
Research and development	192	388
Sales and marketing	100	298
General and administrative	336	927
	<u>\$ 925</u>	<u>\$ 2,469</u>

Future annual payments under non-cancelable operating leases in the aggregate at May 31, 2019, are summarized as follows:

(in thousands)	May 31, 2019
2020	\$ 2,920
2021	2,338
2022	2,133
2023	2,131
2024 and thereafter	3,227
Total lease payments	<u>\$ 12,749</u>

The following table presents supplemental cash flow and other information related to leases for the nine months ended:

(in thousands)	Feb 29, 2020
Cash paid for amounts included in the measurement of lease liabilities	
Operating cash flows from operating leases	\$ 1,767
ROU assets obtained in exchange for lease liabilities	
Operating leases	5,595

15. COMMITMENTS AND CONTINGENCIES

Legal Proceedings

The Company is involved in various legal proceedings, including commercial, intellectual property, product liability, and regulatory matters of a nature considered normal for its business. The Company accrues for amounts related to these matters if it is probable that a liability has been incurred, and an amount can be reasonably estimated. The Company discloses such matters when there is at least a reasonable possibility that a material loss may have been incurred. However, the Company cannot predict the outcome of any litigation or the potential for future litigation.

C.R. Bard, Inc. v. AngioDynamics, Inc.

On January 11, 2012, C.R. Bard, Inc. ("Bard") filed a suit in the United States District Court of Utah claiming certain of the Company's implantable port products infringe on three U.S. patents held by Bard (the "Utah Action"). Bard's complaint sought unspecified damages and other relief. The Company filed petitions for reexamination in the US Patent and Trademark Office ("USPTO") seeking to invalidate all three patents asserted by Bard in the litigation. The Company's petitions were granted and 40 of Bard's 41 patent claims were rejected and, following further proceedings, the Patent Office issued a Final Rejection of all 40 claims subject to reexamination. Thereafter, Bard filed appeals to the USPTO Board of Appeals and Interferences for all three reexaminations which were decided as follows: For US Patent No. 7,785,302, the rejections of six of the ten claims under reexamination were affirmed, but were reversed on four of the ten claims. For U.S. Patent No. 7,959,615 the rejections of eight of the ten claims under reexamination were affirmed but the rejections of the other two of the ten claims were reversed. In the third, for U.S. Patent No. 7,947,022 the rejections of all twenty claims under reexamination were affirmed. Thereafter, Bard sought Rehearing in all three appeals and the Company sought Rehearing in the '302 and '615 appeals. The PTO denied all three Rehearing Requests, but modified its characterization of one prior art reference for the '302 and '022 decisions.

Bard filed appeals to the Federal Circuit Court of Appeals in all three reexams and the Company Cross-Appealed for the '302 and the '615 reexams. MedComp also filed an Amicus Brief in support of the Company on November 22, 2017. Meanwhile, on July 12, 2017 Bard assigned the asserted patents to Bard Peripheral Vascular, Inc. ("BPV") which was added as co-Appellant before the Federal Circuit and as a co-Plaintiff in the Utah action. An oral hearing was held on September 5, 2018 and the Court rendered its decision on September 28, 2018, affirming that claims 1-5 and 10 of the '615 patent were invalid, but that claims 6-7 of the 615 patent and claims 1-4 of the 302 patent were valid over the prior art references considered in the Reexamination proceedings. The Federal Circuit also reversed the PTAB's claim construction ruling and remanded for consideration of obviousness for the remaining claims under the new claim construction ruling and for further findings with respect to whether one of the asserted references qualified as a printed publication. On January 28, 2019, on remand, the USPTO reversed the rejections of the '302 claims 1-10, '022 claims 1-20 and '615 claims 8-9. The USPTO has since issued Inter Partes Reexamination Certificates for the '302 Patent for the '022 patent and for the '615 patent. The Company thereafter filed a Motion to Unstay the Utah Case and that motion was granted. On November 4, 2019 the Court held a joint Status Conference among the Company's Utah Action and two other cases filed by Bard on the same patents against MedComp and

Smiths. The Court set a schedule for defendant's Motions to Dismiss or Transfer. The Company filed its motion on November 25, 2019; and Bard filed a responsive brief and a motion for venue discovery on December 9, 2019. The Company filed a responsive brief on December 16, 2019 and Bard filed a reply on December 23, 2019. On February 27, 2020, the Court referred all non-dispositive motions to Magistrate Furse and on March 3, 2020 the Court granted Bard's Motion for Venue Discovery and denied the Company's transfer motion without prejudice to re-filing after completion of the venue discovery, but no later than June 30, 2020. The parties have since stipulated to a schedule for completing venue discovery. The Company believes these claims are without merit and intends to defend them vigorously. The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.

On March 10, 2015, Bard and BPV filed suit in the United States District Court for the District of Delaware (the "Delaware Action") claiming certain of the Company's implantable port products infringe on three other U.S. patents held by Bard, which are different from those asserted in the Utah action. Bard's complaint seeks unspecified damages and other relief. On June 1, 2015, the Company filed two motions in response to Bard's Complaint - one sought transfer to the District of Utah where the Utah Action is currently pending, and the other sought dismissal of the entire complaint on grounds that none of the claims in the asserted patents is directed to patent eligible subject matter under Section 101 of the Patent Statute and in light of recent authority from the U. S. Supreme Court.

On January 12, 2016, the Court issued a decision denying both motions. A Markman hearing was held on March 10, 2017 and the Court issued its Claim Construction Order on May 19, 2017. On May 19, 2017, Bard served its Final Infringement Contentions and on June 2, 2017, the Company served its Final Invalidity Contentions.

On October 20, 2017, the scheduling order for the case was amended to, among other things, set a trial date commencing July 23, 2018. The parties completed Expert Discovery in January 2018 and completed briefing on their respective case dispositive motions on April 27, 2018. On June 26, 2018, the Court denied all case dispositive motions, ruling that issues of material fact remained in dispute. On July 9, 2018, the Court continued the trial until March 2019. On January 9, 2019 the Court held a further claim construction hearing to resolve two outstanding claim construction issues prior to trial. A Report and Recommendation (by Magistrate-Judge Fallon) was issued on February 11, 2019 and entered by the Court on February 28, 2019. Jury selection was held on Friday March 1, 2019 and trial began on March 4, 2019. On day four of the jury trial, at the close of C.R. Bard's case, the Court granted the Company's oral motion for judgment as a matter of law under rule 50(a) as well as its motions for summary judgement on the grounds that the asserted patents are invalid, ineligible, not infringed and not willfully infringed. On April 5, 2019, Bard filed a precautionary Notice of Appeal to the Federal Circuit. On April 26, 2019, the District Court issued a Memorandum and Order confirming the grant of judgment in the Company's favor of patent ineligibility, non-infringement, patent invalidity and no willful infringement. Meanwhile, on May 10, 2019, the Company filed a Motion for Attorney fees and non-taxable expenses under 35 USC Sec. 285. On May 21, 2019, the Court issued a Memorandum and Order which, inter alia, stayed proceedings on the Company's fee Motion and the Company's equitable claims pending appeal; and entered Final Judgment on May 21, 2019 as well. Bard filed a second Notice of Appeal on May 23, 2019. Both appeals have since been consolidated and Bard's opening brief was filed on September 27, 2019; the Company's answering brief was filed on January 15, 2020; and Bard's reply brief was filed on March 4, 2020. A hearing date has not yet been scheduled. The Company maintains its belief that Bard's claims are without merit. The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.

AngioDynamics, Inc. v. C.R. Bard, Inc.

On May 30, 2017, the Company commenced an action in the United States District Court for the Northern District of New York entitled *AngioDynamics, Inc. v. C.R. Bard, Inc. and Bard Access Systems, Inc.* ("Bard"). In this action, the Company alleges that Bard has illegally tied the sales of its tip location systems to the sales of its PICCs. The Company alleges that this practice violates the federal antitrust laws and has had, and continues to have, an anti-competitive effect in the market for PICCs. The Company seeks both monetary damages and injunctive relief. Bard moved to dismiss on September 8, 2017. On August 6, 2018 the court denied Bard's motion in its entirety. Discovery is largely complete, and the case is currently proceeding to summary judgment and trial.

Merz North America Settlement

On May 16, 2019, Merz North America, Inc. ("Merz") commenced an action in the United States District Court for the Southern District of New York entitled *Merz North America, Inc. v. AngioDynamics, Inc.* In this action, Merz alleged breach of contract against AngioDynamics based on a March 1, 2016 Distribution Agreement. On June 28, 2019, AngioDynamics

reached a settlement with Merz. AngioDynamics made a lump-sum payment of \$2.5 million to Merz in return for dismissal of the case with prejudice during the first quarter. Merz filed a stipulation of dismissal with the Court on July 23, 2019.

16. ACQUISITION, RESTRUCTURING, AND OTHER ITEMS, NET

Acquisition, Restructuring and Other Items

For the three and nine months ended February 29, 2020 and February 28, 2019 acquisition, restructuring and other items, net consisted of:

(in thousands)	Three months ended		Nine months ended	
	Feb 29, 2020	Feb 28, 2019	Feb 29, 2020	Feb 28, 2019
Legal ⁽¹⁾	\$ 637	\$ 1,778	\$ 1,989	\$ 5,524
Mergers and acquisitions ⁽²⁾	154	292	782	3,153
Transition service agreement ⁽³⁾	(386)	—	(1,720)	—
Divestiture ⁽⁴⁾	781	—	2,241	—
Restructuring	—	10	26	266
Other	379	470	1,168	757
Total	\$ 1,565	\$ 2,550	\$ 4,486	\$ 9,700

(1) Legal expenses related to litigation that is outside the normal course of business.

(2) Mergers and acquisitions expenses related to investment banking, legal and due diligence.

(3) Transition services agreement that was entered into as a result of the sale of the Fluid Management business.

(4) Divestiture expenses incurred to transition manufacturing from Glens Falls, NY to Queensbury, NY.

Included in the \$2.0 million in legal for the nine months ended February 29, 2020 is a \$0.4 million settlement received for the Biolitec bankruptcy litigation. The settlement received offsets legal expenses paid related to the settlement proceedings.

Restructuring

The Company evaluates its performance and looks for opportunities to improve the overall operations of the Company on an ongoing basis. As a result of this evaluation, certain restructuring initiatives are taken to enhance the Company's overall operations.

Operational Consolidation

On February 1, 2017, the Company announced to employees an operational consolidation plan (the "plan") to consolidate its manufacturing facilities in Manchester, GA and Denmead, UK into the Glens Falls and Queensbury, NY facilities. This plan will streamline and optimize the manufacturing functions into one centralized location increasing the utilization of the Glens Falls and Queensbury facilities, optimizing inventory and reducing cost of goods sold through savings in overhead expenses and direct labor. The restructuring activities associated with the plan were completed in the fourth quarter of fiscal year 2018 with immaterial regulatory filing costs incurred through August 31, 2019.

17. ACCUMULATED OTHER COMPREHENSIVE LOSS

Changes in each component of accumulated other comprehensive loss, net of tax, are as follows for the three and nine months ended February 29, 2020:

(in thousands)	Three months ended Feb 29, 2020
	Foreign currency translation loss
Balance at November 30, 2019	\$ (1,272)
Other comprehensive income before reclassifications, net of tax	8
Amounts reclassified from accumulated other comprehensive loss	—
Net other comprehensive income	\$ 8
Balance at February 29, 2020	\$ (1,264)

(in thousands)	Nine months ended Feb 29, 2020
	Foreign currency translation loss
Balance at May 31, 2019	\$ (1,352)
Other comprehensive income before reclassifications, net of tax	88
Amounts reclassified from accumulated other comprehensive loss	—
Net other comprehensive income	\$ 88
Balance at February 29, 2020	\$ (1,264)

18. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

The following table provides a description of recent accounting pronouncements that may have a material effect on the Company's consolidated financial statements:

Recently Issued Accounting Pronouncements - Adopted

Standard	Description	Date Adopted	Effect on the Consolidated Financial Statements
ASU 2016-02, <i>Leases (Topic 842)</i>	This ASU increases transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. For leases with a term of twelve months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and liabilities.	June 1, 2019	Refer to Note 14, Leases, for the required disclosures related to adopting this standard.

Recently Issued Accounting Pronouncements - Not Yet Applicable or Adopted

Standard	Description	Effective Date	Effect on the Consolidated Financial Statements
ASU 2018-13, <i>Fair Value Measurement (Topic 820)</i>	This ASU removes, modifies and adds various disclosure requirements related to fair value disclosures. Disclosures related to transfers between fair value hierarchy levels will be removed and further detail around changes in unrealized gains and losses for the period and unobservable inputs used in determining level 3 fair value measurements will be added, among other changes.	June 1, 2020	The Company is currently assessing the impact of this standard on the consolidated financial statements.
ASU 2016-13, <i>Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>	This ASU replaces the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates.	June 1, 2020	The Company is currently assessing the impact of this standard on the consolidated financial statements.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

The following information should be read together with the consolidated financial statements and the notes thereto and other information included elsewhere in this quarterly report on Form 10-Q.

Forward-Looking Statements

This quarterly report on Form 10-Q, including the sections entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations," contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from our expectations. Factors that may affect our actual results achieved include, without limitation, our ability to develop existing and new products, future actions by FDA or other regulatory agencies, results of pending or future clinical trials, the results of ongoing litigation, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, our ability to integrate purchased businesses and other factors including natural disasters and pandemics (such as the scope, scale and duration of the impact of the novel coronavirus, COVID-19). Other risks and uncertainties include, but are not limited to, the factors described from time to time in our reports filed with the SEC.

Although we believe that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this quarterly report on Form 10-Q will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. Any forward-looking statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, speak only as of the date made. AngioDynamics disclaims any obligation to update the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date stated, or if no date is stated, as of the date of this document.

Executive Overview

We design, manufacture and sell a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Our devices are generally used in minimally invasive, image-guided procedures. Many of our products are intended to be used once and then discarded, or they may be temporarily implanted for short- or longer-term use.

Our business operations cross a variety of markets. Our financial performance is impacted by changing market dynamics, which have included an emergence of value-based purchasing by healthcare providers, consolidation of healthcare providers, the increased role of the consumer in health care decision-making and an aging population, among others. In addition, our growth is impacted by changes within our sector, such as the merging of competitors to gain scale and influence; changes in the regulatory environment for medical device; and fluctuations in the global economy.

Our sales and profitability growth also depends, in part, on the introduction of new and innovative products, together with ongoing enhancements to our existing products. Expansions to our product offerings are created through internal product development, technology licensing and strategic alliances. We recognize the importance of, and intend to continue to make investments in research and development activities and business development opportunities and feel confident that our existing capital structure and free cash flow generation will allow us to properly fund those activities.

We sell our products in the United States primarily through a direct sales force, and outside the U.S. through a combination of a direct sales and distributor relationships. We expect our businesses to grow in both sales and profitability through geographic expansion, market penetration, new product introductions and increasing our direct presence internationally.

On December 17, 2019, the Company acquired the C3 Wave tip location asset from Medical Components Inc. for an aggregate purchase price of \$10.0 million with \$5.0 million of potential future contingent consideration related to technical milestones. This acquisition fills a gap in the Vascular Access portfolio and supports the Company's strategic plan. The Company accounted for this acquisition as an asset purchase. The Company recorded the amount paid at closing as inventory

of \$0.6 million and intangible assets of a trademark of \$0.9 million and product technology of \$8.5 million. The intangible asset will be amortized over 15 years. The contingent consideration comprises technical milestones and will be accounted for when the contingency is resolved or becomes probable and reasonably estimable under ASC 450.

On October 2, 2019, the Company entered into a share purchase agreement to acquire Eximo Medical, Ltd., a pre-commercial stage medical device company and its proprietary 355nm B Laser Atherectomy technology. The aggregate purchase price of \$60.7 million included an upfront payment of \$45.8 million and contingent consideration with an estimated fair value of \$14.9 million. This acquisition expands and complements the Company's Vascular Interventions and Therapies product portfolio by adding the 355nm B Laser Atherectomy technology which treats Peripheral Artery Disease.

On May 31, 2019, the Company completed the sale of the NAMIC Fluid Management business (the "Divestiture") and all of the assets used primarily in connection with the Fluid Management business to Medline Industries, Inc. ("Medline") pursuant to an asset purchase agreement dated April 17, 2019 (the "Asset Purchase Agreement"). Total consideration received by the Company for the Divestiture in the fourth quarter of fiscal year 2019 was \$169.2 million in cash and resulted in a gain of \$46.6 million after working capital adjustments of \$0.6 million. A portion of the net proceeds were used on June 3, 2019 to retire the outstanding balance on the Term Loan and Revolving Facility and the remaining net proceeds will continue to be invested in the business.

The COVID-19 global pandemic may pose significant risks to our business. It is too early to quantify the impact this situation will have on revenue and profits for the remainder of our fiscal year ended May 31, 2020 or beyond, but the public health actions being undertaken to reduce spread of the virus are and may continue to create significant disruptions with respect to consumer demand, hospital operating procedures and workflow, our ability to continue to manufacture products and the reliability of our supply chain. Accordingly, management is evaluating the Company's liquidity position, communicating with and monitoring the actions of our customers and suppliers, and reviewing our near-term financial performance as we manage the Company through the uncertainty related to the coronavirus.

As of the date of this report:

1. our field based sales personnel are restricted from traveling, both in the interests of their health as well as at the request of our customers as they seek to increase critical care capacity;
2. our office-based employees have been instructed to work remotely, and
3. our manufacturing facility in Queensbury, New York is operating under our business continuity plan with precautions including, without limitation, creating small "work pods", increasing distancing and regularly monitoring temperatures.

We anticipate that guidance and restrictions from the Center for Medicaid Services, hospitals and hospital systems to reduce "elective-like" procedures and prioritize critical care and coronavirus patients will have a materially adverse impact on certain procedure volumes to which certain of our products relate.

As discussed in more detail below, we will closely monitor our liquidity and capital resources through the disruption caused by the COVID-19 pandemic.

In evaluating the operating performance of our business, management focuses on revenue, gross margin, operating income, earnings per share and cash flow from operations. A summary of these key financial metrics for the three and nine months ended February 29, 2020 compared to the three and nine months ended February 28, 2019 follows:

Three months ended February 29, 2020:

- Revenue increased by 6.5% to \$69.8 million
- Gross margin decreased 40 bps to 57.8%
- Operating loss increased by \$2.6 million to \$6.2 million
- Loss per share from continuing operations increased by \$0.03 to a loss of \$0.15

Nine months ended February 29, 2020:

- Revenue increased by 3.2% to \$205.8 million
- Gross margin increased 80 bps to 58.3%
- Operating loss decreased by \$1.8 million to \$10.5 million
- Loss per share from continuing operations improved by \$0.11 to a loss of \$0.26

Critical Accounting Policies and Use of Estimates

Our significant accounting policies are summarized in Note 1 to Notes to Consolidated Financial Statements included in our Form 10-K. While all these significant accounting policies affect the reporting of our financial condition and results of operations, we view certain of these policies as critical. Policies determined to be critical are those policies that have the most significant impact on our financial statements and require us to use a greater degree of judgment and/or estimates. Actual results may differ from those estimates. As of the third quarter of fiscal year 2020, the following updates were made as a result of the COVID-19 global pandemic:

Goodwill and Intangible Assets

Intangible assets other than goodwill, indefinite lived intangible assets and in process research and development ("IP R&D") are amortized over their estimated useful lives, which range between two to eighteen years, on either a straight-line basis over the expected period of benefit or as revenues are earned from the sales of the related products. We periodically review the estimated useful lives of our intangible assets and review such assets for impairment whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. If an intangible asset is considered to be impaired, the amount of the impairment will equal the excess of the carrying value over the fair value of the asset.

Goodwill and other intangible assets that have indefinite useful lives are not amortized, but rather, are tested for impairment annually or more frequently if impairment indicators arise. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. Goodwill and intangible assets have been recorded at either incurred or allocated cost. Allocated costs were based on respective fair market values at the date of acquisition.

For goodwill, the impairment test requires a comparison of the estimated fair value of the reporting unit to which the goodwill is assigned to the carrying value of the assets and liabilities of that reporting unit. The determination of reporting units also requires management judgment. The Company considers whether a reporting unit exists within a reportable segment based on the availability of discrete financial information. If the carrying value of the reporting unit exceeds the fair value of the reporting unit, the carrying value of the reporting unit's goodwill is reduced to its fair value through an adjustment to the goodwill balance, resulting in an impairment charge.

Whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable we test intangible assets for impairment based on estimates of future cash flows. Based upon the ultimate scope and scale of the COVID-19 global pandemic, there may be materially negative impacts to the assumptions made with respect to our goodwill and other long lived intangible assets that could result in an impairment of such assets.

The Company operates as a single operating segment with one reporting unit and consequently evaluates goodwill for impairment based on an evaluation of the fair value of the Company as a whole. The Company determined the fair value of the reporting unit based on the market valuation approach and concluded that it was not more-likely-than-not that the fair value of the Company's reporting unit was less than its carrying value.

New Accounting Pronouncements

Information regarding new accounting pronouncements is included in Note 18 to our consolidated financial statements in this Quarterly Report on Form 10-Q.

Results of Operations for the Three Months Ended February 29, 2020 and February 28, 2019

For the three months ended February 29, 2020, the Company reported net loss of \$5.7 million, or \$0.15 per diluted share, on net sales of \$69.8 million, compared with net loss of \$4.6 million from continuing operations, or \$0.12 loss per diluted share, on net sales of \$65.5 million during the same quarter of the prior year.

Net Sales

Net sales - Net sales are derived from the sale of products and related freight charges, less discounts and returns.

Net sales for the three months ended February 29, 2020 and February 28, 2019:

(in thousands)	Three months ended		
	Feb 29, 2020	Feb 28, 2019	% Growth
Net Sales by Global Business Unit			
Vascular Interventions & Therapies	\$ 30,552	\$ 29,298	4.3%
Vascular Access	24,642	22,348	10.3%
Oncology	14,586	13,878	5.1%
Total	<u>\$ 69,780</u>	<u>\$ 65,524</u>	6.5%
Net Sales by Geography			
United States	\$ 54,889	\$ 53,400	2.8%
International	14,891	12,124	22.8%
Total	<u>\$ 69,780</u>	<u>\$ 65,524</u>	6.5%

For the three months ended February 29, 2020, net sales increased \$4.3 million to \$69.8 million compared to the same period in the prior year.

Vascular Interventions & Therapies

- Total Vascular Interventions & Therapies sales increased \$1.3 million primarily attributable to strong performance in the AngioVac business which grew \$1.5 million and in Core Peripheral products which grew \$1.3 million year over year. During the quarter, the Company continued to see strong case volumes in AngioVac, which increased 33% from the prior year due to increased adoption of the Company's unique technology and the launch of the next generation of the AngioVac product. There was \$0.2 million in sales of the atherectomy product that was acquired as part of the Eximo acquisition in the second quarter of fiscal year 2020. These increases were partially offset by the termination of the Asclera distribution agreement, which contributed \$1.7 million of revenue in the prior year.
- U.S. Vascular Interventions & Therapies sales increased \$0.5 million due to increased case volume in AngioVac and increased Core Peripheral product sales which was partially offset by the termination of the Asclera distribution agreement, which contributed \$1.7 million of revenue in the prior year.
- International Vascular Interventions & Therapies sales increased \$0.8 million.

Vascular Access

- Total Vascular Access sales increased \$2.3 million due to increased sales across all product lines along with sales from the acquisition of the C3 Wave tip location asset from Medical Components Inc. BioFlo product lines comprise 51% of overall Vascular Access sales compared to 52% a year ago.
- U.S. Vascular Access sales increased \$1.1 million across all product lines, including a \$0.5 million increase in Port sales as a result of the new GPO arrangement with Premier.
- International Vascular Access sales increased by \$1.2 million as the Company continues to expand its global reach of its Vascular Access product offerings.

Oncology

- Total Oncology sales increased \$0.7 million year over year primarily due to increased NanoKnife capital sales of \$1.0 million and increased NanoKnife disposable sales of \$0.5 million. This was partially offset by decreased sales of RadioFrequency Ablation disposables.
- U.S. Oncology sales decreased by \$0.1 million due to a decrease in RadioFrequency Ablation and Microwave disposable sales. This was partially offset by an increase in NanoKnife capital sales of \$0.6 million and NanoKnife disposable sales of \$0.2 million.
- International Oncology sales increased by \$0.8 million year over year as a result of increased NanoKnife capital sales of \$0.4 million and NanoKnife disposable sales of \$0.3 million.

Gross Profit, Operating expenses, and Other income (expense)

(in thousands)	Three months ended		
	Feb 29, 2020	Feb 28, 2019	% Change
Gross profit	\$ 40,299	\$ 38,163	5.6 %
Gross profit % of sales	57.8 %	58.2 %	
Research and development	\$ 8,395	\$ 6,915	21.4 %
% of sales	12.0 %	10.6 %	
Selling and marketing	\$ 20,934	\$ 18,385	13.9 %
% of sales	30.0 %	28.1 %	
General and administrative	\$ 10,203	\$ 8,718	17.0 %
% of sales	14.6 %	13.3 %	

Gross profit - Gross profit consists of net sales less the cost of goods sold, which includes the costs of materials, products purchased from third parties and sold by us, manufacturing personnel, royalties, freight, business insurance, depreciation of property and equipment and other manufacturing overhead, exclusive of intangible amortization.

Gross profit increased by \$2.1 million compared to the prior year. The increase is primarily attributable to the following:

- Sales volume and price, driven by AngioVac and NanoKnife capital sales, positively contributed \$4.5 million year over year.
- Mix negatively impacted gross margin by \$0.9 million as a result of higher VA sales.
- Net productivity and a prior year supplier reimbursement negatively impacted gross margin by \$0.7 million.
- The termination of the Asclera distribution agreement negatively impacted gross margin by \$0.7 million.

Research and development expenses - Research and development (“R&D”) expenses include internal and external costs to develop new products, enhance existing products, validate new and enhanced products, and manage clinical, regulatory and medical affairs.

R&D expense increased \$1.5 million compared to the prior year. The increase is primarily attributable to the following:

- Compensation and benefits increased approximately \$0.3 million due to increased variable compensation along with increased headcount as a result of the Eximo acquisition.
- Research and development spend related to the Eximo acquisition contributed \$1.2 million.

Sales and marketing expenses - Sales and marketing (“S&M”) expenses consist primarily of salaries, commissions, travel and related business expenses, attendance at medical society meetings, product promotions and marketing activities.

S&M expense increased \$2.5 million compared to the prior year. The increase is primarily attributable to the following:

- Compensation and benefits increase of approximately \$1.1 million which is primarily attributed to increased variable compensation and increased commissions as a result of NanoKnife capital sales.
- Expenses related to the build-out of the Eximo sales and marketing teams to prepare for full product launch of \$1.2 million.
- Other sales and marketing expenses increased \$0.5 million to support company-wide initiatives was partially offset by decreased outside service fees of \$0.2 million.

General and administrative expenses - General and administrative (“G&A”) expenses include executive management, finance, information technology, human resources, business development, legal, and the administrative and professional costs associated with those activities.

G&A expense increased \$1.5 million compared to the prior year. The increase is primarily attributable to the following:

- Legal and professional fees relating to ongoing litigation that is within the normal course of business increased \$1.2 million, primarily related to the Company’s suit against C.R. Bard.

- Compensation and benefits increased approximately \$0.3 million primarily as a result of variable based compensation offset by the reversal of share based compensation expense of \$0.7 million for employees who are no longer with the Company.
- Increased consultant spend of \$0.2 million, increased expenses related to the Eximo acquisition to integrate the business of \$0.2 million and increased travel and expenses of \$0.1 million.

(in thousands)	Three months ended		
	Feb 29, 2020	Feb 28, 2019	\$ Change
Amortization of intangibles	\$ 5,019	\$ 4,660	\$ 359
Change in fair value of contingent consideration	\$ 419	\$ 609	\$ (190)
Acquisition, restructuring and other items, net	\$ 1,565	\$ 2,550	\$ (985)
Other expense	\$ (297)	\$ (1,708)	\$ 1,411

Amortization of intangibles - Represents the amount of amortization expense that was taken on intangibles assets held by the Company.

- Amortization expense increased \$0.4 million compared to the prior year. The addition of the Eximo product technology intangible asset and the C3 Wave tip location intangible assets increased intangible assets by \$60.3 million and \$9.4 million, respectively. These additions resulted in additional amortization expense of \$1.1 million. This was partially offset by the write-off of the Merz intangible in the fourth quarter of fiscal year 2019 and other intangibles that became fully amortized.

Change in fair value of contingent consideration - Represents changes in contingent consideration driven by changes to estimated future payments on earn-out liabilities created through acquisitions and amortization of present value discounts on long-term contingent consideration.

- The change from the prior year is due to decreased amortization on the RadiaDyne contingent consideration as a result of the gain of \$8.4 million that was recorded in the fourth quarter of fiscal year 2019 and the gain of \$0.6 million that was recorded in the first quarter of fiscal year 2020. The Eximo contingent consideration was recorded for \$14.9 million in the second quarter of fiscal year 2020. In addition, the final minimum payment of \$1.2 million was paid for the Microsulis contingent consideration during the first quarter of fiscal 2020.

Acquisition, restructuring and other items, net - Represents costs associated with mergers and acquisitions, restructuring expenses, legal costs that are related to litigation that is not in the ordinary course of business, legal settlements and other one-time items.

Acquisition, restructuring and other items, net decreased by \$1.0 million compared to the prior year. The decrease is primarily attributable to the following:

- M&A expense of \$0.2 million was incurred in the third quarter of fiscal year 2020 compared to \$0.3 million in the prior year.
- Legal expense, related to litigation that is outside of the normal course of business, of \$0.6 million was recorded in the third quarter of fiscal year 2020 compared to \$1.8 million in the prior year.
- In the third quarter of fiscal year 2020, the Company incurred \$0.8 million of expense to move manufacturing facilities as a result of the sale of the Fluid Management business.
- As part of the sale of the Fluid Management business, the Company entered into a transition services agreement with Medline for certain legal, human resource, tax, accounting and information technology services from the Company for a period not to exceed 24 months. As a result of the transition services agreement, the Company invoiced Medline \$0.4 million in the third quarter of fiscal year 2020.
- Other expenses of \$0.4 million in the third quarter of fiscal year 2020 consists of expenses to move the manufacturing of BioSentry products and severance associated with the sale of the Fluid Management business.

Other expenses, net - Other expenses include interest expense, foreign currency impacts, bank fees, and amortization of deferred financing costs.

- The decrease in other expenses from the prior year of \$1.4 million is due to decreased interest expense of \$1.3 million as the Credit Facility was paid down in full at the beginning of the first quarter of fiscal year 2020.

Income Tax Provision (Benefit)

(in thousands)	Three months ended	
	Feb 29, 2020	Feb 28, 2019
Income tax expense (benefit)	\$ (0.8)	\$ (0.8)
Effective tax rate including discrete items	12.6 %	14.4 %

Our effective tax rate including discrete items for the three month periods ended February 29, 2020 and February 28, 2019 was 12.6% and 14.4%, respectively. In fiscal 2020, the Company's effective tax rate differs from the U.S. statutory rate primarily due to the impact of the valuation allowance, foreign taxes, and other non-deductible permanent items (such as non-deductible meals and entertainment, Section 162(m) excess compensation and non-deductible share based compensation).

The estimated annual effective tax rate, however, prior to discrete items was 12.9% in the third quarter of fiscal 2020, as compared to 14.0% for the same period in fiscal 2019.

Results of Operations for the Nine Months Ended February 29, 2020 and February 28, 2019

For the nine months ended February 29, 2020, the Company reported net loss of \$9.7 million, or \$0.26 per diluted share, on net sales of \$205.8 million, compared with net loss of \$13.9 million from continuing operations, or \$0.37 loss per diluted share, on net sales of \$199.5 million during the same quarter of the prior year.

Net Sales

Net sales - Net sales are derived from the sale of products and related freight charges, less discounts and returns.

Net sales for the nine months ended February 29, 2020 and February 28, 2019:

(in thousands)	Nine months ended		
	Feb 29, 2020	Feb 28, 2019	% Growth
Net Sales by Global Business Unit			
Vascular Interventions & Therapies	\$ 90,616	\$ 88,870	2.0%
Vascular Access	70,585	69,861	1.0%
Oncology	44,624	40,720	9.6%
Total	<u>\$ 205,825</u>	<u>\$ 199,451</u>	3.2%
Net Sales by Geography			
United States	\$ 163,381	\$ 161,195	1.4%
International	42,444	38,256	10.9%
Total	<u>\$ 205,825</u>	<u>\$ 199,451</u>	3.2%

For the nine months ended February 29, 2020, net sales increased \$6.4 million to \$205.8 million compared to the same period in the prior year.

Vascular Interventions & Therapies

- Total Vascular Interventions & Therapies sales increased \$1.7 million primarily attributable to strong performance in the AngioVac business which grew \$4.2 million and in Core Peripheral products which grew \$1.6 million year over year. During the period, the Company continued to see strong case volumes in AngioVac, which increased 33% from the prior year due to increased adoption of the Company's unique technology and the launch of the next generation of the AngioVac product. There was \$0.2 million in sales of the atherectomy product that was acquired as part of the Eximo acquisition in the second quarter of fiscal year 2020. These increases were partially offset by the termination of the Asclera distribution agreement, which contributed \$4.8 million of revenue in the prior year.
- U.S. Vascular Interventions & Therapies sales increased \$0.6 million due to increased case volume in AngioVac and increased Core Peripheral product sales which were partially offset by the termination of the Asclera distribution agreement, which contributed \$4.8 million of revenue in the prior year.

- International Vascular Interventions & Therapies sales increased \$1.1 million due to increased volume in Angiographic catheters primarily in EMEA (Europe, the Middle East and Africa).

Vascular Access

- Total Vascular Access sales increased \$0.7 million driven by Midline and Dialysis sales of \$1.2 million which were partially offset by decreases in PICCs and Ports. BioFlo product lines comprise 51% of overall Vascular Access sales in both the current year and prior year.
- U.S. Vascular Access sales decreased by \$1.6 million due to competitive pressures in the PICC product lines and lower Port sales. This was partially offset by growth in Midlines and in Dialysis products which continued to gain traction in the marketplace.
- International Vascular Access sales increased by \$2.3 million as the Company continues to expand its global reach of its Vascular Access product offerings.

Oncology

- Total Oncology sales increased \$3.9 million year over year primarily due to increased NanoKnife capital sales of \$3.8 million along with \$1.8 million and \$0.9 million in increased sales of balloons and BioSentry products, respectively. This was partially offset by decreased sales of Radiofrequency Ablation and NanoKnife disposable sales.
- U.S. Oncology sales increased by \$3.2 million, driven by NanoKnife capital sales of \$1.9 million, balloon sales of \$1.8 million and BioSentry sales of \$0.7 million. This was partially offset by a decrease in RadioFrequency Ablation and NanoKnife disposable sales.
- International Oncology sales increased by \$0.7 million year over year as a result of increased NanoKnife capital sales of \$1.9 million. This was offset by decreased RadioFrequency product sales.

Gross Profit, Operating expenses, and Other income (expense)

(in thousands)	Nine months ended		
	Feb 29, 2020	Feb 28, 2019	% Change
Gross profit	\$ 120,060	\$ 114,668	4.7 %
Gross profit % of sales	58.3 %	57.5 %	
Research and development	\$ 22,450	\$ 21,365	5.1 %
% of sales	10.9 %	10.7 %	
Selling and marketing	\$ 60,427	\$ 56,054	7.8 %
% of sales	29.4 %	28.1 %	
General and administrative	\$ 29,651	\$ 26,414	12.3 %
% of sales	14.4 %	13.2 %	

Gross profit - Gross profit consists of net sales less the cost of goods sold, which includes the costs of materials, products purchased from third parties and sold by us, manufacturing personnel, royalties, freight, business insurance, depreciation of property and equipment and other manufacturing overhead, exclusive of intangible amortization.

Gross profit increased by \$5.4 million compared to the prior year. The increase is primarily attributable to the following:

- Sales volume and price driven by AngioVac and NanoKnife capital sales positively contributed \$7.1 million year over year.
- Net productivity contributed \$1.1 million of favorability.
- Mix negatively impacted gross margin by \$0.6 million as a result of higher VA sales.
- Other items, including a royalty step-up and a prior year supplier reimbursement, negatively impacted gross margin by \$0.2 million.
- The termination of the Asclera distribution agreement negatively impacted gross margin by \$2.1 million.

Research and development expenses - Research and development (“R&D”) expenses include internal and external costs to develop new products, enhance existing products, validate new and enhanced products, and manage clinical, regulatory and medical affairs.

R&D expense increased \$1.1 million compared to the prior year. The increase is primarily attributable to the following:

- Compensation and benefits increased approximately \$0.3 million due to increased variable compensation along with increased headcount as a result of the Eximo acquisition.
- Research and development spend related to the Eximo acquisition contributed \$1.7 million.
- Other R&D expenses, including facilities, samples and project initiatives timing resulted in a decrease of \$0.8 million.

Sales and marketing expenses - Sales and marketing (“S&M”) expenses consist primarily of salaries, commissions, travel and related business expenses, attendance at medical society meetings, product promotions and marketing activities.

S&M expense increased \$4.4 million compared to the prior year. The increase is primarily attributable to the following:

- Compensation and benefits increase of approximately \$2.4 million which is primarily attributed to increased variable compensation and increased commissions as a result of NanoKnife capital sales.
- Expenses related to the build-out of the Eximo sales and marketing teams to prepare for full product launch of \$1.5 million.
- Other sales and marketing expenses increased \$1.0 million to support company-wide initiatives.
- Outside service fees decreased \$0.4 million.

General and administrative expenses - General and administrative (“G&A”) expenses include executive management, finance, information technology, human resources, business development, legal, and the administrative and professional costs associated with those activities.

G&A expense increased \$3.2 million compared to the prior year. The increase is primarily attributable to the following:

- Legal and professional fees relating to ongoing litigation that is within the normal course of business increased \$3.5 million, primarily related to the Company's suit against C.R. Bard.
- Compensation and benefits decreased approximately \$1.4 million primarily as a result of the reversal of share based compensation expense for employees who are no longer with the Company along with the timing of fully vested share based compensation awards..
- Increased expenses related to the Eximo acquisition to integrate the business of \$0.5 million and increased other expenses of \$0.6 million.

(in thousands)	Nine months ended		
	Feb 29, 2020	Feb 28, 2019	\$ Change
Amortization of intangibles	\$ 13,417	\$ 12,599	\$ 818
Change in fair value of contingent consideration	\$ 116	\$ 865	\$ (749)
Acquisition, restructuring and other items, net	\$ 4,486	\$ 9,700	\$ (5,214)
Other expense	\$ (739)	\$ (3,761)	\$ 3,022

Amortization of intangibles - Represents the amount of amortization expense that was taken on intangibles assets held by the Company.

- Amortization expense increased \$0.8 million compared to the prior year. The addition of the Eximo product technology intangible asset and the C3 Wave tip location intangible assets increased intangible assets by \$60.3 million and \$9.4 million, respectively. These additions resulted in additional amortization expense of \$1.8 million. This was partially offset by the write-off of the Merz intangible in the fourth quarter of fiscal year 2019 and other intangibles that became fully amortized.

Change in fair value of contingent consideration - Represents changes in contingent consideration driven by changes to estimated future payments on earn-out liabilities created through acquisitions and amortization of present value discounts on long-term contingent consideration.

- The change from the prior year is due to the gain of \$0.6 million that was recorded on the technical milestones for the RadiaDyne contingent consideration in the first quarter of fiscal year 2020. The gain was partially offset by decreased amortization on the RadiaDyne contingent consideration as a result of the first quarter gain along with the \$8.4 million

gain that was recorded in the fourth quarter of fiscal year 2019. The Eximo contingent consideration was recorded for \$14.9 million in the second quarter of fiscal year 2020. In addition, the final minimum payment of \$1.2 million was paid for the Microsulis contingent consideration during the first quarter of fiscal 2020.

Acquisition, restructuring and other items, net - Represents costs associated with mergers and acquisitions, restructuring expenses, legal costs that are related to litigation that is not in the ordinary course of business, legal settlements and other one-time items.

Acquisition, restructuring and other items, net decreased by \$5.2 million compared to the prior year. The decrease is primarily attributable to the following:

- M&A expense of \$0.8 million was incurred in fiscal year 2020 compared to \$3.2 million in the prior year.
- Legal expense, related to litigation that is outside of the normal course of business, of \$2.0 million was recorded in fiscal year 2020, which includes an offset of \$0.4 million from the Biolitec bankruptcy settlement, compared to \$5.5 million in the prior year.
- In fiscal year 2020, the Company incurred \$2.2 million of expense to move manufacturing facilities as a result of the sale of the Fluid Management business.
- As part of the sale of the Fluid Management business, the Company entered into a transition services agreement with Medline for certain legal, human resource, tax, accounting and information technology services from the Company for a period not to exceed 24 months. As a result of the transition services agreement, the Company invoiced Medline \$1.7 million in fiscal year 2020.
- Other expenses of \$1.2 million in fiscal year 2020 consists of expenses to move the manufacturing of BioSentry products and severance associated with the sale of the Fluid Management business.

Other expenses, net - Other expenses include interest expense, foreign currency impacts, bank fees, and amortization of deferred financing costs.

- The decrease in other expenses from the prior year of \$3.0 million is due to decreased interest expense of \$3.4 million as the Credit Facility was paid down in full at the beginning of the first quarter of fiscal year 2020. In addition to the decrease in interest expense, interest income increased \$0.3 million from the prior year as a result of increased cash due to proceeds from the sale of the Fluid Management business. These increases are partially offset by the write-off of the deferred financing fees that were associated with the old Credit Facility of \$0.5 million. Other expenses also include foreign currency fluctuations which increased by \$0.2 million.

Income Tax Provision (Benefit)

(in thousands)	Nine months ended	
	Feb 29, 2020	Feb 28, 2019
Income tax expense (benefit)	\$ (1.5)	\$ (2.1)
Effective tax rate including discrete items	13.4 %	13.6 %

Our effective tax rate including discrete items for the nine month periods ended February 29, 2020 and February 28, 2019 was 13.4% and 13.6%, respectively. In fiscal 2020, the Company's effective tax rate differs from the U.S. statutory rate primarily due to the impact of the valuation allowance, foreign taxes, and other non-deductible permanent items (such as non-deductible meals and entertainment, Section 162(m) excess compensation and non-deductible share based compensation).

The estimated annual effective tax rate, however, prior to discrete items was 12.9% in the third quarter of fiscal 2020, as compared to 14.0% for the same period in fiscal 2019.

Liquidity and Capital Resources

We are continuously and critically reviewing our liquidity and anticipated capital requirements in light of the significant uncertainty created by the COVID-19 global pandemic. We believe that our current cash on hand and availability under our revolving credit facility provide sufficient liquidity to meet our anticipated needs for capital for at least the next 12 months. We are closely monitoring receivables and payables. In addition, we believe that our recently increased inventory levels provide additional risk mitigation in the event we incur a manufacturing disruption.

Our cash and cash equivalents totaled \$27.2 million as of February 29, 2020, compared with \$227.6 million as of May 31, 2019. As of February 29, 2020, there was \$15.0 million in debt outstanding and as of May 31, 2019 there was \$132.5 million principal debt outstanding. The fair value of contingent consideration liability as of February 29, 2020 and May 31, 2019, was \$27.3 million and \$13.5 million, respectively.

The table below summarizes our cash flows for the nine months ended February 29, 2020 and February 28, 2019:

(in thousands)	Nine Months Ended	
	Feb 29, 2020	Feb 28, 2019
Cash used in:		
Operating activities	\$ (18,434)	\$ 12,428
Investing activities	(61,866)	(85,873)
Financing activities	(120,189)	41,173
Effect of exchange rate changes on cash and cash equivalents	8	(120)
Net change in cash and cash equivalents	\$ (200,481)	\$ (32,392)

During the nine months ended February 29, 2020 and February 28, 2019, cash flows consisted of the following:

Cash used in operating activities

Nine months ended February 29, 2020:

- Net loss of \$9.7 million plus the non-cash items, primarily driven by depreciation and amortization and share based compensation, contributed to cash used in operations of \$18.4 million.
- Working capital was negatively impacted by increased inventory on hand of \$14.0 million and decreased accounts payable and accrued liabilities of \$18.0 million. Accounts receivable had a favorable impact on working capital as a result of the sale of the Fluid Management business.

Nine months ended February 28, 2019:

- Net income was driven by increased sales and increased gross profit. This was partially offset by higher operating expenses in research and development, selling and marketing and general administrative as well as costs related to our acquisition and restructuring activities.
- The Company continues to focus on optimizing its cash conversion cycle. In the third quarter of fiscal year 2019, working capital was negatively impacted by increased inventory on hand of \$2.7 million. Days sales outstanding ("DSO") increased as a result of increased sales in the third quarter. This had a \$3.9 million negative impact on working capital. Also, the \$12.7 million DOJ settlement payment that was made during the first quarter of fiscal year 2019 negatively impacted working capital from accounts payable and accrued liabilities.

Cash used in investing activities

Nine months ended February 29, 2020 and February 28, 2019:

- \$5.8 million in fixed asset additions versus \$2.3 million in the prior year.
- \$10.0 million cash payment to Medical Components Inc to acquire the C3 wave tip location asset and \$45.8 million cash payment to acquire Eximo Medical Ltd. in fiscal year 2020 compared to a \$37.0 million cash payment to acquire the BioSentry product from SSC and a \$47.9 million cash payment to acquire RadiaDyne in fiscal year 2019. Refer to Note 2 to the financial statements.

Cash used in financing activities

Nine months ended February 29, 2020 and February 28, 2019:

- \$132.5 million repayment of long-term debt in conjunction with the new Credit Agreement that was entered into at the beginning of the first quarter of fiscal year 2020. Refer to Note 8 of the financial statements.

- \$15.0 million draw on the revolver in fiscal year 2020 for the acquisition of the C3 Wave tip location asset compared with \$55.0 million draw on the revolver in fiscal year 2019 as a result of the RadiaDyne acquisition described in Note 2 to the financial statements.
- \$13.8 million repayment on the Term Loan in the prior year. This was consistent with the required amortization payment on the Term Loan.
- \$0.7 million of outlays from stock option and ESPP activity versus \$2.0 million in proceeds in the prior year.
- \$1.2 million payment on earn-out liabilities in the current year compared to \$2.1 million in the prior year.

On June 3, 2019 and in connection with the completion of the Fluid Management divestiture, the Company repaid all amounts outstanding under its existing Credit Agreement and entered into a new Credit Agreement. The Credit Agreement provides for a \$125.0 million secured revolving credit facility, which includes an uncommitted expansion feature that allows the Company to increase the total revolving commitments and/or add new tranches of term loans in an aggregate amount not to exceed \$75.0 million. The Credit Agreement includes customary representations, warranties and covenants, and acceleration, indemnity and events of default provisions, including, among other things, two financial covenants. One financial covenant requires us to maintain a fixed charge coverage ratio of not less than 1.25 to 1.00. The other financial covenant requires us to maintain a total leverage ratio of not greater than 3.00 to 1.00. The total leverage ratio is based upon our trailing twelve months total adjusted EBITDA (as defined in the Credit Agreement). The amount that we can borrow under our Credit Agreement is directly based on our leverage ratio.

On December 17, 2019, the Company made a \$15.0 million draw on the revolving credit facility as part of the acquisition of the C3 Wave tip location asset from Medical Components Inc. that is described Note 2 to the financial statements. We believe that our current cash and investment balances, together with cash generated from operations and access to our revolving credit facility, will provide sufficient liquidity to meet our anticipated needs for capital for at least the next 12 months. If we seek to make significant acquisitions of other businesses or technologies in the future for cash, we may require external financing.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Foreign Currency Exchange Rate Risk

We are exposed to market risk from changes in currency exchange rates, as well as interest rate fluctuations on our credit facility and investments that could impact our results of operations and financial position.

We transact sales in currencies other than the U.S. Dollar, particularly the Euro, British pound and Canadian dollar. Approximately 7% of our sales in the third quarter of fiscal 2020 were denominated in foreign currencies. We do not have expenses denominated in foreign currencies at the level of our sales and as a result, our profitability is exposed to currency fluctuations. When the U.S. Dollar strengthens, our sales and gross profit will be negatively impacted. In addition, we have assets and liabilities denominated in non-functional currencies which are remeasured at each reporting period, with the offset to changes presented as a component of Other (Expenses) Income. Significant non-functional balances include accounts receivable due from a subsection of our international customers.

Interest Rate Risk

On June 3, 2019, we entered into the Credit Agreement which provides for a \$125 million Revolving Facility. Interest on the facility will be based, at the Company's option, on a base rate of LIBOR plus an applicable margin tied to the Company's total leverage ratio and having ranges between 0.25% and 0.75% for base rate loans and between 1.25% and 1.75% for LIBOR loans. In the event of default, the interest rate may be increased by 2.0%.

Concentration of Credit Risk

Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents, our credit facility and trade accounts receivable.

The Company maintains cash and cash equivalents at various institutions and performs periodic evaluations of the relative credit standings of these financial institutions to ensure their credit worthiness. In addition, the Credit Agreement is structured across five above investment grade banks. The Company has the ability to draw equally amongst the five banks which limits the concentration of credit risk of one institution.

Concentration of credit risk with respect to trade accounts receivable is limited due to the large number of customers that purchase products from the Company. No single customer represents more than 10% of total sales. The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business. Although the Company does not currently foresee a significant credit risk associated with the outstanding accounts receivable, repayment is dependent upon the financial stability of our customers.

Item 4. Controls and Procedures.

Evaluation of disclosure controls and procedures

As of the end of the period covered by this report, our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended. Based on that evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective to provide reasonable assurance that the information required to be disclosed by us in reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting for the fiscal quarter ended February 29, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

AngioDynamics, Inc. and Subsidiaries

PART II: OTHER INFORMATION

Item 1. Legal Proceedings.

C.R. Bard, Inc. v. AngioDynamics, Inc.

On January 11, 2012, C.R. Bard, Inc. ("Bard") filed a suit in the United States District Court of Utah claiming certain of the Company's implantable port products infringe on three U.S. patents held by Bard (the "Utah Action"). Bard's complaint sought unspecified damages and other relief. The Company filed petitions for reexamination in the US Patent and Trademark Office ("USPTO") seeking to invalidate all three patents asserted by Bard in the litigation. The Company's petitions were granted and 40 of Bard's 41 patent claims were rejected and, following further proceedings, the Patent Office issued a Final Rejection of all 40 claims subject to reexamination. Thereafter, Bard filed appeals to the USPTO Board of Appeals and Interferences for all three reexaminations which were decided as follows: For US Patent No. 7,785,302, the rejections of six of the ten claims under reexamination were affirmed, but were reversed on four of the ten claims. For U.S. Patent No. 7,959,615 the rejections of eight of the ten claims under reexamination were affirmed but the rejections of the other two of the ten claims were reversed. In the third, for U.S. Patent No. 7,947,022 the rejections of all twenty claims under reexamination were affirmed. Thereafter, Bard sought Rehearing in all three appeals and the Company sought Rehearing in the '302 and '615 appeals. The PTO denied all three Rehearing Requests, but modified its characterization of one prior art reference for the '302 and '022 decisions.

Bard filed appeals to the Federal Circuit Court of Appeals in all three reexams and the Company Cross-Appealed for the '302 and the '615 reexams. MedComp also filed an Amicus Brief in support of the Company on November 22, 2017. Meanwhile, on July 12, 2017 Bard assigned the asserted patents to Bard Peripheral Vascular, Inc. ("BPV") which was added as co-Appellant before the Federal Circuit and as a co-Plaintiff in the Utah action. An oral hearing was held on September 5, 2018 and the Court rendered its decision on September 28, 2018, affirming that claims 1-5 and 10 of the '615 patent were invalid, but that claims 6-7 of the 615 patent and claims 1-4 of the 302 patent were valid over the prior art references considered in the Reexamination proceedings. The Federal Circuit also reversed the PTAB's claim construction ruling and remanded for consideration of obviousness for the remaining claims under the new claim construction ruling and for further findings with respect to whether one of the asserted references qualified as a printed publication. On January 28, 2019, on remand, the USPTO reversed the rejections of the '302 claims 1-10, '022 claims 1-20 and '615 claims 8-9. The USPTO has since issued Inter Partes Reexamination Certificates for the '302 Patent for the '022 patent and for the '615 patent. The Company thereafter filed a Motion to Unstay the Utah Case and that motion was granted. On November 4, 2019 the Court held a joint Status Conference among the Company's Utah Action and two other cases filed by Bard on the same patents against MedComp and Smiths. The Court set a schedule for defendant's Motions to Dismiss or Transfer. The Company filed its motion on November 25, 2019; and Bard filed a responsive brief and a motion for venue discovery on December 9, 2019. The Company filed a responsive brief on December 16, 2019 and Bard filed a reply on December 23, 2019. On February 27, 2020, the Court referred all non-dispositive motions to Magistrate Furse and on March 3, 2020 the Court granted Bard's Motion for Venue Discovery and denied the Company's transfer motion without prejudice to re-filing after completion of the venue discovery, but no later than June 30, 2020. The parties have since stipulated to a schedule for completing venue discovery. The Company believes these claims are without merit and intends to defend them vigorously. The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.

On March 10, 2015, Bard and BPV filed suit in the United States District Court for the District of Delaware (the "Delaware Action") claiming certain of the Company's implantable port products infringe on three other U.S. patents held by Bard, which are different from those asserted in the Utah action. Bard's complaint seeks unspecified damages and other relief. On June 1, 2015, the Company filed two motions in response to Bard's Complaint - one sought transfer to the District of Utah where the Utah Action is currently pending, and the other sought dismissal of the entire complaint on grounds that none of the claims in the asserted patents is directed to patent eligible subject matter under Section 101 of the Patent Statute and in light of recent authority from the U. S. Supreme Court.

On January 12, 2016, the Court issued a decision denying both motions. A Markman hearing was held on March 10, 2017 and the Court issued its Claim Construction Order on May 19, 2017. On May 19, 2017, Bard served its Final Infringement Contentions and on June 2, 2017, the Company served its Final Invalidity Contentions.

On October 20, 2017, the scheduling order for the case was amended to, among other things, set a trial date commencing July 23, 2018. The parties completed Expert Discovery in January 2018 and completed briefing on their respective case

dispositive motions on April 27, 2018. On June 26, 2018, the Court denied all case dispositive motions, ruling that issues of material fact remained in dispute. On July 9, 2018, the Court continued the trial until March 2019. On January 9, 2019 the Court held a further claim construction hearing to resolve two outstanding claim construction issues prior to trial. A Report and Recommendation (by Magistrate-Judge Fallon) was issued on February 11, 2019 and entered by the Court on February 28, 2019. Jury selection was held on Friday March 1, 2019 and trial began on March 4, 2019. On day four of the jury trial, at the close of C.R. Bard's case, the Court granted the Company's oral motion for judgment as a matter of law under rule 50(a) as well as its motions for summary judgment on the grounds that the asserted patents are invalid, ineligible, not infringed and not willfully infringed. On April 5, 2019, Bard filed a precautionary Notice of Appeal to the Federal Circuit. On April 26, 2019, the District Court issued a Memorandum and Order confirming the grant of judgment in the Company's favor of patent ineligibility, non-infringement, patent invalidity and no willful infringement. Meanwhile, on May 10, 2019, the Company filed a Motion for Attorney fees and non-taxable expenses under 35 USC Sec. 285. On May 21, 2019, the Court issued a Memorandum and Order which, inter alia, stayed proceedings on the Company's fee Motion and the Company's equitable claims pending appeal; and entered Final Judgment on May 21, 2019 as well. Bard filed a second Notice of Appeal on May 23, 2019. Both appeals have since been consolidated and Bard's opening brief was filed on September 27, 2019; the Company's answering brief was filed on January 15, 2020; and Bard's reply brief was filed on March 4, 2020. A hearing date has not yet been scheduled. The Company maintains its belief that Bard's claims are without merit. The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.

AngioDynamics, Inc. v. C.R. Bard, Inc.

On May 30, 2017, the Company commenced an action in the United States District Court for the Northern District of New York entitled *AngioDynamics, Inc. v. C.R. Bard, Inc. and Bard Access Systems, Inc.* ("Bard"). In this action, the Company alleges that Bard has illegally tied the sales of its tip location systems to the sales of its PICCs. The Company alleges that this practice violates the federal antitrust laws and has had, and continues to have, an anti-competitive effect in the market for PICCs. The Company seeks both monetary damages and injunctive relief. Bard moved to dismiss on September 8, 2017. On August 6, 2018 the court denied Bard's motion in its entirety. Discovery is largely complete, and the case is currently proceeding to summary judgment and trial.

Merz North America Settlement

On May 16, 2019, Merz North America, Inc. ("Merz") commenced an action in the United States District Court for the Southern District of New York entitled *Merz North America, Inc. v. AngioDynamics, Inc.* In this action, Merz alleged breach of contract against AngioDynamics based on a March 1, 2016 Distribution Agreement. On June 28, 2019, AngioDynamics reached a settlement with Merz. AngioDynamics made a lump-sum payment of \$2.5 million to Merz in return for dismissal of the case with prejudice during the first quarter. Merz filed a stipulation of dismissal with the Court on July 23, 2019.

Item 1A. Risk Factors.

In addition to information set forth in this report, you should carefully consider the factors discussed in “Part I, Item 1A. Risk Factors” of our annual report on Form 10-K for our fiscal year ended May 31, 2019 which set forth information relating to important risks and uncertainties that could materially adversely affect our business, financial condition or operating results. You should review and consider such Risk Factors in making any investment decision with respect to our securities. An investment in our securities continues to involve a high degree of risk. Except as set forth below, there have been no material changes to the risk factors previously disclosed in our annual report on Form 10-K.

We are dependent on the proper functioning of our critical facilities, our supply chain and distribution networks and our sales force as well as the financial stability of our customers, all of which could be negatively impacted by the coronavirus in a manner that could materially adversely affect our business, financial condition or results of operations.

Our ability to manufacture products may be materially adversely impacted by the coronavirus.

The Novel Coronavirus Disease 2019 (COVID-19) (“coronavirus”) is impacting worldwide economic activity. Estimates for economic growth have been reduced as a result of the coronavirus, which may have a corresponding effect on our sales activity. The virus continues to spread globally, has been declared a pandemic by the World Health Organization and has spread to over 100 countries, including the United States. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will likely continue to result in significant disruptions to the global economy, as well as businesses and capital markets around the world. With the spread of the coronavirus to the United States and other countries, it is unclear how economic activity and work flows might be impacted on a worldwide basis. Many employers in the United States are requiring their employees to work from home or not come into their offices or facilities. We manufacture primarily out of one facility in Queensbury, New York, and partially out of a facility in Glens Falls, New York. If the manufacturing capabilities of these two sites are impacted as a result of the coronavirus, it may not be possible for us to timely manufacture relevant products at required levels or at all. A reduction or interruption in any of our manufacturing processes could have a material adverse effect on our business, results of operations, financial condition and cash flows.

We also might be unable to obtain products, product components, or sterilized products from our suppliers and vendors due to the additional constraints on suppliers created by the coronavirus. Any delays in delivery of or shortages in products and components could interrupt and delay manufacturing of our products and result in the cancellation of orders for our products.

Our sales may be materially adversely impacted by the coronavirus.

Our sales force functions by meeting in person with physicians and health care providers to discuss our products. The coronavirus may negatively affect demand for our products by limiting the ability of our sales personnel to maintain their customary contacts with customers for a period of time. We may also find that distributors will have to prioritize their work load and may be forced to slow their activities as a result of the coronavirus. As a result, we cannot assure you that our sales force or distributors will increase or maintain our current levels of unit sales or increase or maintain our current unit pricing, which, in turn, could have a material adverse effect on our business, results of operations, financial condition and cash flows. In addition, there is a risk that our international distributors will not be financially viable due to the impact of coronavirus in their respective countries.

We may also experience significant and unpredictable reductions in demand for certain products as our health care customers re-prioritize the treatment of patients and divert resources away from non-coronavirus areas. For example, elective surgeries are being de-prioritized which will negatively impact the usage of certain products, including, without limitation, our EVLT and core products and certain Oncology products. As a result of coronavirus, our customers and vendors may experience financial difficulties or be unable to borrow money to fund their operations, which may adversely impact their ability to purchase our products or pay for our products on a timely basis, if at all.

The execution of our clinical studies may be materially adversely impacted by the coronavirus.

Our future business prospects are highly dependent on generating, collecting and disseminating data pursuant to clinical trials. Clinical trials, including, without limitation, our DIRECT Study, studying the use of NanoKnife to treat pancreatic cancer, and our Pathfinder Registry, collecting data on the use of our Atherectomy laser, may be materially impacted by the coronavirus as hospitals prioritize treating coronavirus patients and creating capacity. Delays in the initiation of sites or enrollment of patients in these and other clinical studies, may have a material adverse effect on our results of operations and future business prospects.

Our ability to raise capital may be materially adversely impacted by the coronavirus.

Any sustained disruption in the capital markets from the COVID-19 pandemic could negatively impact our ability to raise capital. As of the end of our third fiscal quarter we have a strong balance sheet and do not anticipate the need to raise additional capital. However, we cannot predict when the macro-economic disruption stemming from the coronavirus will ebb or when the

economy will return to pre-coronavirus levels, if at all. If the macro-economic disruption continues for pro-longed periods we may need to raise additional capital and capital may not be available on acceptable terms, or at all.

The impact of the coronavirus on economic activity, and its effect on our manufacturing facility, supply chain and distribution networks, our sales force and our customers are uncertain at this time and could have a material adverse effect on our results, especially to the extent these effects persist or exacerbate over an extended period of time.

Value of our goodwill and other long lived intangible assets may be materially impaired as a result of COVID-19.

A significant portion of our assets consists of goodwill, intangible assets and fixed assets, the carrying value of which may be reduced if we determine that those assets are impaired.

Most of our intangible and fixed assets have finite useful lives and are amortized or depreciated over their useful lives on either a straight-line basis or over the expected period of benefit or as revenues are earned from the sales of the related products. The underlying assumptions regarding the estimated useful lives of these intangible assets are reviewed quarterly and more often if an event or circumstance occurs making it likely that the carrying value of the assets may not be recoverable and are adjusted through accelerated amortization if necessary. Whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable we test intangible assets for impairment based on estimates of future cash flows. Based upon the ultimate scope and scale of the COVID-19 global pandemic, there may be materially negative impacts to the assumptions made with respect to our goodwill and other long lived intangible assets that could result in an impairment of such assets.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

The following table provides information with respect to the shares of the Company's common stock repurchased during the nine months ended February 29, 2020:

	Issuer Purchases of Equity Securities			
	Total Number of Shares Purchased	Average Price Paid per Share	Total Number of Shares Purchased as Part of Publicly Announced Programs (1)	Maximum Approximate Dollar Value of Shares that May Yet Be Purchased Under Plans or Programs (1)
December 1, 2019 - December 31, 2019	736	\$ 15.62	—	\$ —
January 1, 2020 - January 31, 2020	490	\$ 15.02	—	\$ —
February 1, 2020 - February 29, 2020	490	\$ 12.76	—	\$ —
Total	1,716	\$ 14.63	—	—

(1) These amounts are not applicable as the Company currently does not have a share repurchase program in effect.

Item 3. Defaults on Senior Securities.

None.

Item 4. Mine Safety Disclosures.

None.

Item 5. Other Information.

None.

Item 6**EXHIBIT INDEX**

No.	Description
31.1	Certification pursuant to Rule 13a-14(a) or 15d-14 under the Securities Exchange Act of 1934.
31.2	Certification pursuant to Rule 13a-14(a) or 15d-14 under the Securities Exchange Act of 1934.
32.1	Certification of Chief Executive Officer pursuant to Title 18, United States Code, Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2	Certification of Chief Financial Officer pursuant to Title 18, United States Code, Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS	The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document
101.SCH	XBRL Schema Document
101.CAL	XBRL Calculation Linkbase Documents
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Labels Linkbase Documents
101.PRE	XBRL Presentation Linkbase Documents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ANGIODYNAMICS, INC.
(Registrant)

Date: April 8, 2020

/ S / JAMES C. CLEMMER

**James C. Clemmer, President,
Chief Executive Officer
(Principal Executive Officer)**

Date: April 8, 2020

/ S / STEPHEN A. TROWBRIDGE

**Stephen A. Trowbridge, Executive Vice President,
Chief Financial Officer
(Principal Financial and Accounting Officer)**

CERTIFICATION

I, James C. Clemmer, certify that:

1. I have reviewed this quarterly report on Form 10-Q of AngioDynamics, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: April 8, 2020

/S/ JAMES C. CLEMMER

James C. Clemmer, President,
Chief Executive Officer

CERTIFICATION

I, Stephen A. Trowbridge, certify that:

1. I have reviewed this quarterly report on Form 10-Q of AngioDynamics, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: April 8, 2020

/ S / STEPHEN A. TROWBRIDGE

Stephen A. Trowbridge, Executive Vice President,
Chief Financial Officer

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO TITLE 18,
UNITED STATES CODE, SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, James C. Clemmer, President, Chief Executive Officer and Director of ANGIODYNAMICS, Inc. (the "Company"), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that, to the best of my knowledge:

1. the quarterly report on Form 10-Q of the Company for the fiscal quarter ended February 29, 2020 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and
2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: April 8, 2020

/ S / JAMES C. CLEMMER

James C. Clemmer, President,
Chief Executive Officer

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO TITLE 18,
UNITED STATES CODE, SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Stephen A. Trowbridge, Senior Vice President, General Counsel and Interim Chief Financial Officer of ANGIODYNAMICS, Inc. (the "Company"), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that, to the best of my knowledge:

1. the quarterly report on Form 10-Q of the Company for the fiscal quarter ended February 29, 2020 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and
2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: April 8, 2020

/ S / STEPHEN A. TROWBRIDGE

Stephen A. Trowbridge, Executive Vice President,
Chief Financial Officer